https://www.mdc-berlin.de/de/veroeffentlichungstypen/clinical-journal-club

Als gemeinsame Einrichtung von MDC und Charité fördert das Experimental and Clinical Research Center die Zusammenarbeit zwischen Grundlagenwissenschaftlern und klinischen Forschern. Hier werden neue Ansätze für Diagnose, Prävention und Therapie von Herz-Kreislauf- und Stoffwechselerkrankungen, Krebs sowie neurologischen Erkrankungen entwickelt und zeitnah am Patienten eingesetzt. Sie sind eingelanden, um uns beizutreten. Bewerben Sie sich!

A 51-year old woman presented to the primary care clinic with mild worsening of chronic abdominal pain. On physical examination, the liver was enlarged. Magnetic resonance cholangiopancreatography revealed a markedly enlarged liver with numerous cystic structures (a three-dimensional maximum-intensity-projection reconstruction is shown in the figure). What is the most likely underlying diagnosis?

Alpha1-antitrypsin deficiency

Amebiasis

Autosomal dominant polycystic kidney disease

Hepatocellular adenomas

Tuberous sclerosis

The correct answer is autosomal dominant polycystic kidney disease. In autosomal dominant polycystic kidney disease, cysts can develop in a range of sites, including the liver, pancreas, and seminal vesicles. No signs of intracystic hemorrhage, rupture, or infection were found.

Die tuberöse Sklerose ist eine autosomal-dominante Erbkrankheit, die mit Fehlbildungen und Tumoren des Gehirns, Hautveränderungen und meist gutartigen Tumoren in anderen Organsystemen einhergeht und klinisch häufig durch epileptische Anfälle und kognitive Behinderungen gekennzeichnet ist.
Die Prävalenz der Erkrankung liegt bei Neugeborenen bei etwa 1:8000. Nach den Erstbeschreibern, den französischen Neurologen Désiré-Magloire Bourneville (1840–1909) und Édouard Brissaud (1852–1909) sowie dem britischen Hautarzt John James Pringle (1855–1922) wird diese Erkrankung häufig auch als Bourneville-Pringle-Syndrom oder Bourneville-Brissaud-Pringle-Syndrom bezeichnet. Im englischen Sprachraum hat sich der Begriff Tuberous Sclerosis Complex (TSC) eingebürgert, um den Komplex verschiedener Symptome und Krankheitsbilder bei dieser Erkrankung aus der Gruppe der Phakomatosen hervorzuheben.

Außerhalb des Gehirns treten in den Nieren gutartige Tumoren, sogenannte Angiomyolipome, und Nierenzysten auf. Diese Veränderungen machen häufig keine Beschwerden, können aber selten bösartig entarten. Im Herzen werden bei vielen Kindern von Geburt an so genannte Rhabdomyome, Tumore des Muskelgewebes, diagnostiziert. Diese von Friedrich Daniel von Recklinghausen (1833–1910) erstmals beschriebenen Tumoren machen in den meisten Fällen keine ernsthaften Probleme.

So far, it has been mapped to two genetic loci, TSC1 and TSC2. TSC2 is contiguous with PKD1, the gene involved in one form of polycystic kidney disease (PKD). Gross deletions affecting both genes may account for the 2% of individuals with TSC who also develop polycystic kidney disease in childhood. *TSC2* has been associated with a more severe form of TSC. Estimates of the proportion of TSC caused by *TSC2* range from 55% to 90%. TSC1 and TSC2 are both tumor suppressor genes that function according to Knudson's "two hit" hypothesis. That is, a second random mutation must occur before a tumor can develop. This explains why, despite its high penetrance, TSC has wide expressivity.

Research paper

Development and validation of a penumbra-based predictive model for thrombolysis outcome in acute ischemic stroke patients

A B S T R A C T

The use of thrombolysis in acute ischemic stroke is restricted to a small proportion of patients because of the rigid 4·5-h window. With advanced imaging-based patient selection strategy, rescuing penumbra is critical to improving clinical outcomes. In this study, we included 155 acute ischemic stroke patients (84 patients in training dataset, age from 43 to 80, 59 males; 71 patients in validation dataset, age from 36 to 80, 45 males) who underwent MR scan within the first 9-h after onset, from 7 independent centers. Based on the mismatch concept, penumbra and core area were identified and quantitatively analyzed. Moreover, predictive models were developed and validated to provide an approach for identifying patients who may benefit from thrombolytic therapy. Predictive models were constructed, and corresponding areas under the curve (AUC) were calculated to explore their performances in predicting clinical outcomes. Additionally, the models were validated using an independent dataset both on Day-7 and Day-90. Significant correlations were detected between the mismatch ratio and clinical assessments in both the training and validation datasets. Treatment option, baseline systolic blood pressure, National Institutes of Health Stroke Scale score, mismatch ratio, and three regional radiological parameters were selected as biomarkers in the combined model to predict clinical outcomes of acute ischemic stroke patients. With the external validation, this predictive model reached AUCs of 0·863 as short-term validation and 0·778 as long-term validation. This model has the potential to provide quantitative biomarkers that aid patient selection for thrombolysis either within or beyond the current time window.



Penumbra:
Halbschatten



Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke

The time to initiate intravenous thrombolysis for acute ischemic stroke is generally limited to within 4.5 hours after the onset of symptoms. Some trials have suggested that the treatment window may be extended in patients who are shown to have ischemic but not yet infarcted brain tissue on imaging. We conducted a multicenter, randomized, placebo-controlled trial involving patients with ischemic stroke who had hypoperfused but salvageable regions of brain detected on automated perfusion imaging. The patients were randomly assigned to receive intravenous alteplase or placebo between 4.5 and 9.0 hours after the onset of stroke or on awakening with stroke (if within 9 hours from the midpoint of sleep). The primary outcome was a score of 0 or 1 on the modified Rankin scale, on which scores range from 0 (no symptoms) to 6 (death), at 90 days. The risk ratio for the primary outcome was adjusted for age and clinical severity at baseline. Critically hypoperfused brain was measured on perfusion MRI or CT perfusion imaging according to a delayed arrival of an injected tracer agent (time to maximum of the residue function exceeding 6 seconds).



Characteristic	Alteplase (N=113)	Placebo (N=112)
Age — yr	73.7±11.7	71.0±12.7
Male sex — no. (%)	59 (52.2)	66 (58.9)
Median NIHSS score (IQR)†	12.0 (8.0–17.0)	10.0 (6.0–16.5)
Clinical history of atrial fibrillation — no. (%)	46 (40.7)	36 (32.1)
Geographic region — no. (%)		
Australia, New Zealand, and Finland	90 (79.6)	88 (78.6)
Taiwan	23 (20.4)	24 (21.4)
Time from stroke onset to randomization — no. (%)		
>4.5 to 6.0 hr	12 (10.6)	11 (9.8)
>6.0 to 9.0 hr	28 (24.8)	28 (25.0)
Awoke with stroke symptoms‡	73 (64.6)	73 (65.2)
Median time from stroke onset to hospital arrival (IQR) — min	308 (227–362)	293 (230–357)
Median time from stroke onset to initiation of intravenous therapy (IQR) — min	432 (374–488)	450 (374–500)
Median time from hospital arrival to initiation of intravenous therapy (IQR) — min	124 (81–179)	127 (87–171)
Imaging result		
Large-vessel occlusion — no.(%)§	78 (69.0)	81 (72.3)
Median volume of irreversibly injured ischemic-core tissue at initial imaging (IQR) — ml¶	4.6 (0–23.2)	2.4 (0–19.5)
Median perfusion-lesion volume at initial imaging (IQR) — ml‖	74.3 (40.1–134.0)	78 (47.7–111.8)

Patients

Patients were eligible for inclusion if they were at least 18 years of age; had excellent functional status before enrollment (defined by a score of <2 on the modified Rankin scale, on which scores range from 0 [no neurologic deficit] to 6 [death]); had a stroke with a clinical severity score at presentation of 4 to 26 on the National Institutes of Health Stroke Scale (NIHSS), on which scores range from 0 to 42, with higher scores indicating greater deficit; and had hypoperfused but salvageable regions of brain detected on automated perfusion imaging. Occlusion of a large cerebral vessel was not a prerequisite for inclusion. Imaging techniques included CT perfusion imaging or perfusion-diffusion MRI, and images were processed with the use of a research version of RAPID automated software (Stanford University and iSchemaView).

In estimating the volume of irreversibly injured ischemic-core tissue, we used a threshold for relative cerebral blood flow of less than 30% of that in normal brain regions or we used diffusion-weighted MRI. Critically hypoperfused brain was measured on perfusion MRI or CT perfusion imaging according to a delayed arrival of an injected tracer agent (time to maximum of the residue function exceeding 6 seconds). Perfusion lesion–ischemic core mismatch was defined as a ratio greater than 1.2 between the volume of hypoperfusion and the volume of the ischemic core, an absolute difference in volume greater than 10 ml, and an ischemic-core volume of less than 70 ml. Patients were not eligible if the investigator was considering the use of endovascular thrombectomy at the time of enrollment.

Trial Interventions

The patients were randomly assigned, in a 1:1 ratio, to receive either alteplase (0.9 mg per kilogram of body weight [maximum, 90 mg], administered intravenously as a 10% bolus and 90% infusion over 1 hour) or matching placebo. Randomization was performed through a centralized website, with stratification according to geographic region (Australia, New Zealand, and Finland vs. Taiwan) and time of intervention (>4.5 to 6.0 hours after stroke onset, >6.0 to 9.0 hours after stroke onset, or on awakening with stroke symptoms). Guideline-based care for acute stroke was recommended for all patients. From 2010 through February 2018, the guidelines did not include the use of endovascular thrombectomy in extended time windows.

Outcomes

The primary outcome was a score of 0 or 1 on the modified Rankin scale at 90 days (indicating an excellent functional outcome with a return to all usual activities). The risk ratio for the primary outcome was adjusted for age and clinical severity of stroke (NIHSS score) at baseline. The secondary clinical outcomes were the score (0 to 6) on the modified Rankin scale at 90 days (with the distribution of scores in each trial group used in an ordinal analysis to assess functional improvement).



Scores on the Modified Rankin Scale at 90 Days. Shown is the distribution of the scores on the modified Rankin scale at 90 days for all patients (intention-to-treat analysis). Scores range from 0 to 6, with 0 indicating no neurologic deficit, 1 no clinically significant disability (return to all usual activities), 2 slight disability (able to handle own affairs without assistance but unable to carry out all previous activities), 3 moderate disability requiring some help (e.g., with shopping, cleaning, and finances but able to walk unassisted), 4 moderately severe disability (unable to attend to bodily needs without assistance and unable to walk unassisted), 5 severe disability (requiring constant nursing care and attention), and 6 death. The primary outcome of a score of 0 or 1 on the modified Rankin scale occurred in a higher percentage of patients in the alteplase group than in the placebo group. A secondary ordinal analysis of the distribution of scores on the modified Rankin scale at 90 days did not show a significant between-group difference in functional improvement (common odds ratio, 1.55; 95% confidence interval, 0.96 to 2.49). Percentages may not total 100 because of rounding.

With respect to the tertiary outcomes, recanalization at 24 hours after stroke occurred in 67.3% of the patients in the alteplase group and in 39.4% of those in the placebo group (adjusted risk ratio, 1.68; 95% CI, 1.29 to 2.19), and early major neurologic improvement at 24 hours occurred in 23.9% of the patients in the alteplase group and in 9.8% of those in the placebo group (adjusted risk ratio, 2.76; 95% CI, 1.45 to 5.26). There were no significant interactions observed between trial group and any subgroup, including subgroups defined according to large-vessel occlusion status and time to intervention.

The percentage of patients who died within 90 days after the intervention did not differ significantly between the alteplase group and the placebo group (13 of 113 patients [11.5%] vs. 10 of 112 patients [8.9%]; adjusted risk ratio, 1.17; 95% CI, 0.57 to 2.40; P=0.67). Death within 7 days occurred in 9 of 225 patients (4.0%) in the trial population — 5 in the alteplase group (2 of whom had symptomatic hemorrhage) and 4 in the placebo group. Symptomatic intracranial hemorrhage occurred in 7 of 113 patients (6.2%) in the alteplase group and in 1 of 112 patients (0.9%) in the placebo group (adjusted risk ratio, 7.22; 95% CI, 0.97 to 53.54; P=0.053).

Table 2. Efficacy and Safety Outcomes.*

Outcome	Alteplase (N=113)	Placebo (N=112)	Adjusted Effect Size (95% CI)†	P Value	Unadjusted Effect Size (95% CI)†	P Value
	no./total no. (%)					
Primary outcome						
Score of 0 to 1 on the modified Rankin scale at 90 days‡	40/113 (35.4)	33/112 (29.5)	1.44 (1.01–2.06)	0.04	1.2 (0.82–1.76)	0.35
Secondary outcomes						
Score on the modified Rankin scale at 90 days						
0	14/113 (12.4)	12/112 (10.7)				
1	26/113 (23.0)	21/112 (18.8)				
2	16/113 (14.2)	15/112 (13.4)				
3	15/113 (13.3)	16/112 (14.3)				
4	15/113 (13.3)	24/112 (21.4)				
5	14/113 (12.4)	14/112 (12.5)				
6	13/113 (11.5)	10/112 (8.9)				
Functional improvement§			1.55 (0.96–2.49)		1.18 (0.74–1.87)	
Functional independence¶	56/113 (49.6)	48/112 (42.9)	1.36 (1.06–1.76)		1.16 (0.87–1.54)	
Percentage of reperfusion at 24 hr						
≥90%	53/106 (50.0)	31/109 (28.4)	1.73 (1.22–2.46)		1.76 (1.23–2.51)	
≥50%	76/106 (71.7)	57/109 (52.3)	1.35 (1.09–1.67)		1.37 (1.10–1.70)	
Tertiary outcomes						
Recanalization at 24 hr	72/107 (67.3)	43/109 (39.4%)	1.68 (1.29–2.19)		1.71 (1.30–2.23)	
Major neurologic improvement‖						
At 24 hr	27/113 (23.9)	11/112 (9.8)	2.76 (1.45–5.26)		2.43 (1.27–4.67)	
At 72 hr	32/112 (28.6)	22/112 (19.6)	1.56 (0.97–2.52)		1.45 (0.90–2.34)	
At 90 days	59/101 (58.4)	49/99 (49.5)	1.17 (0.91–1.52)		1.18 (0.91–1.53)	
Safety outcomes						
Death within 90 days after intervention	13/113 (11.5)	10/112 (8.9)	1.17 (0.57–2.40)	0.67	1.29 (0.59–2.82)	0.53
Symptomatic intracranial hemorrhage within 36 hr after intervention	7/113 (6.2)	1/112 (0.9)	7.22 (0.97–53.54)	0.053	6.94 (0.86–55.73)	0.07

* Adjusted analyses of the scores on the modified Rankin scale, death, symptomatic intracerebral hemorrhage, and major neurologic improvement included age and baseline NIHSS score as covariates. Adjusted analyses of reperfusion and recanalization included site of arterial occlusion as a covariate.

† Effect sizes were assessed as risk ratios, except for functional improvement. The 95% confidence intervals for the secondary and tertiary outcomes were not adjusted for multiple comparisons.

‡ Scores on the modified Rankin scale range from 0 to 6, with 0 indicating no neurologic deficit, 1 no clinically significant disability (return to all usual activities), 2 slight disability (able to handle own affairs without assistance but unable to carry out all previous activities), 3 moderate disability requiring some help (e.g., with shopping, cleaning, and finances but able to walk unassisted), 4 moderately severe disability (unable to attend to bodily needs without assistance and unable to walk unassisted), 5 severe disability (requiring constant nursing care and attention), and 6 death.

§ Functional improvement was defined as an improvement of at least 1 point on the modified Rankin scale at 90 days and was assessed as a common odds ratio in an ordinal logistic-regression analysis (with data combined for scores of 5 and 6).

¶ Functional independence was defined as a score of 0 to 2 on the modified Rankin scale at 90 days.

‖ Major neurologic improvement was classified as a reduction in NIHSS score of at least 8 points or a score of 0 or 1 at 24 hours, 72 hours, or 90 days.

Discussion

Among the patients who had acute ischemic stroke and a favorable perfusion-imaging profile detected by automated perfusion imaging, the use of alteplase therapy between 4.5 and 9.0 hours after the onset of stroke or at the time the patient awoke with stroke symptoms resulted in a higher percentage of patients with a score of 0 or 1 on the modified Rankin scale (indicating no or minimal deficits, respectively) than the use of placebo, with an unadjusted absolute between-group difference of 6 percentage points. In an ordinal analysis of the distribution of scores on the modified Rankin scale at 90 days, the lower boundary of the 95% confidence interval of the common odds ratio for functional improvement crossed 1.00 and therefore was unlikely to show a significant difference between the trial groups. Findings for the other outcomes, including recanalization, reperfusion, and early neurologic improvement, were supportive of the observed benefit of alteplase with respect to the primary outcome, but the analyses were not adjusted for multiple comparisons. Limitations of our trial include the premature termination of recruitment at 73% of the planned sample size. We were also unable to show a significant difference in the secondary outcome of functional improvement, as gauged by the 95% confidence interval in an ordinal analysis. In contrast to the adjusted analyses emphasized in the results of the trial, the findings from the unadjusted analyses of primary and secondary outcomes did not differ significantly between trial groups. However, imbalances in the baseline covariates of age and clinical severity of stroke occurred in favor of the placebo group. Our “door-to-needle time” of approximately 2 hours was longer than recommended in the guidelines.

In conclusion, the use of alteplase therapy in patients who had a favorable perfusion-imaging profile between 4.5 and 9 hours after stroke onset or on awakening with stroke symptoms resulted in no or minor neurologic deficits more often than the use of placebo. Because of the limited power of our conclusions as a result of premature termination of the trial and the lack of a significant between-group difference in the secondary outcome of functional improvement, further trials of thrombolysis in this time window are required.

Das in Asien vorkommende Nipah-Virus (NiV, auch NIPV) löst beim Menschen eine häufig tödlich verlaufende Gehirnentzündung aus. Das Virus wird durch Kontakt mit Körperflüssigkeiten und -ausscheidungen infizierter Tiere und Menschen übertragen. Reservoirwirte sind offenbar fruchtfressende Flughunde, von denen es auf andere Tiere und Menschen weitergegeben werden kann. Zwischen September 1998 und April 1999 wurden offiziell 229 Fälle einer schwerverlaufenden, fiebrigen Enzephalitis in Malaysia gemeldet, kurz nach dem Beginn dieser Epidemie auch neun Fälle in Singapur. Hier wurden auch Symptome einer schweren Infektion der Atemwege berichtet. Überwiegend waren Männer betroffen, die in Schlachthäusern arbeiteten; von den Erkrankten starben 48 %. Daher vermutete man sehr schnell einen Zusammenhang mit einer Infektion bei Tieren. Gleichzeitig wurde in Malaysia bei Schweinen ein milder Ausbruch einer fiebrigen Atemwegsinfektion mit ungeklärtem Erreger registriert, der erst später als der gleiche Erreger wie bei den Enzephalitis-Patienten identifiziert wurde. Um die weitere Verbreitung der Epidemie auch beim Menschen zu verhindern, wurden über eine Million Schweine gekeult, was etwa der Hälfte des gesamten malayischen Schweinebestandes entsprach.
Durch die Reduktion des Schweinebestandes und veterinärmedizinische Überwachung konnte der Ausbruch eingedämmt werden. Bisher wurden insgesamt zwölf kleinere Ausbrüche dokumentiert, so in den Jahren 2001 und 2003 in Bangladesch.
Mit etwa 165 Millionen Einwohnern (2017) auf einer Fläche von 147.570 km² steht es nach Einwohnerzahl auf Platz acht der größten Staaten der Erde.



Systematik	
Klassifikation:	Viren
Ordnung:	*Mononegavirales*
Familie:	*Paramyxoviridae*
Gattung:	*Henipavirus*
Art:	*Nipah-Virus*
Taxonomische Merkmale	
Genom:	(-)ssRNA linear
Baltimore:	Gruppe 5
Symmetrie:	helikal
Hülle:	vorhanden
Wissenschaftlicher Name	

Transmission of Nipah Virus — 14 Years of Investigations in Bangladesh

Nipah virus is a highly virulent zoonotic pathogen that can be transmitted between humans. Understanding the dynamics of person-to-person transmission is key to designing effective interventions. We used data from all Nipah virus cases identified during outbreak investigations in Bangladesh from April 2001 through April 2014 to investigate case-patient characteristics associated with onward transmission and factors associated with the risk of infection among patient contacts.

Characteristic	Case Patients†	Secondary Cases	Reproduction No. (95% CI)‡	Relative Infectivity (95% CI)§	P Value	Adjusted Relative Infectivity (95% CI)§
	no./total no. (%)	*no. of secondary cases/case patients*				
Sex						
Female	90/248 (36)	5/90	0.06 (0.02–0.2)	Reference		
Male	158/248 (64)	74/158	0.5 (0.2–0.9)	8.4 (2.0–35)	0.006	NA
Age						
≤14 yr	91/248 (37)	1/91	0.01 (0.00–0.09)	0.01 (0.00–0.1)		0.02 (0.00–0.2)
15 to 29 yr	55/248 (22)	10/55	0.2 (0.06–0.6)	0.2 (0.04–1.0)	<0.001	0.3 (0.05–1.3)
30 to 44 yr	62/248 (25)	31/62	0.5 (0.2–1.3)	0.5 (0.1–2.4)		0.8 (0.2–3.4)
≥45 yr	40/248 (16)	37/40	0.9 (0.3–2.9)	Reference		Reference
Source of infection						
Spillover or unidentified source¶	166/248 (67)	50/166	0.3 (0.1–0.7)	Reference		
Person-to-person	82/248 (33)	29/82	0.4 (0.1–1.1)	1.2 (0.3–4.5)	0.81	NA
Hospitalization after symptom onset						
≤2 days	36/248 (15)	2/36	0.06 (0.01–0.4)	Reference		
3 to 5 days	128/248 (52)	36/128	0.3 (0.1–0.6)	5.1 (0.6–44)	0.18	NA
≥6 days	58/248 (23)	15/58	0.3 (0.08–0.9)	4.7 (0.4–49)		NA
Not hospitalized	26/248 (10)	26/26	1.0 (0.2–5.6)	18 (1.3–252)		NA
Illness outcome‖						
Survived ≤7 days	140/244 (57)	74/140	0.5 (0.1–2.1)	Reference		
Survived >7 days	104/244 (43)	5/104	0.05 (0.01–0.2)	0.09 (0.02–0.4)	0.001	NA
Difficulty breathing						
No	91/243 (37)	2/91	0.02 (0.00–0.1)	Reference		Reference
Yes	152/243 (63)	77/152	0.5 (0.3–1.0)	23 (4.1–130)	<0.001	19 (3.2–114)
Cough						
No	118/242 (49)	25/118	0.2 (0.0– 0.5)	Reference		
Yes	124/242 (51)	54/124	0.4 (0.2–1.0)	2.1 (0.6–7.2)	0.27	NA
Vomiting						
No	110/244 (45)	21/110	0.2 (0.07–0.5)	Reference		
Yes	134/244 (55)	58/134	0.4 (0.2–1.0)	2.3 (0.6–8.0)	0.22	NA

Nipah Virus Case Contacts and Risk Factors Associated with Nipah Virus Infection.

Characteristic	Contacts†	Contacts Infected		Odds Ratio§ (95% CI)	P Value	Adjusted Odds Ratio§ (95% CI)	Adjusted P Value
	no./total no. (%)	*no./total no.*	*% Infected (95% CI)‡*				
Sex							
Female	1289/2606 (49)	22/1288	1.7 (1.1–2.6)	Reference			
Male	1317/2606 (51)	11/1312	0.8 (0.4–1.5)	0.4 (0.2–0.9)	0.02	NA	
Age							
≤14 yr	299/2606 (11)	4/297	1.3 (0.4–3.4)	1.2 (0.3–4.6)	0.90	NA	
15 to 29 yr	827/2606 (32)	10/827	1.2 (0.6–2.2)	0.7 (0.3–2.1)		NA	
30 to 44 yr	833/2606 (32)	11/831	1.3 (0.7–2.4)	0.9 (0.3–2.6)		NA	
≥45 yr	647/2606 (25)	8/645	1.2 (0.5–2.4)	Reference		NA	
Relationship¶							
Spouse	56/2605 (2)	8/56	14.3 (6.4–26)	47 (11–212)			
Close family member	548/2605 (21)	7/547	1.3 (0.5–2.6)	2.0 (0.7–5.6)	<0.001	NA	
Other contact	2001/2605 (77)	18/1996	0.9 (0.5–1.4)	Reference		NA	
Duration of exposure							
≤1 hr	652/2604 (25)	3/652	0.5 (0.1–1.3)	Reference		Reference	
>1 to 6 hr	761/2604 (29)	7/756	0.9 (0.4–1.9)	2.3 (0.5–10)	<0.001	2.2 (0.5–10)	0.005
>6 to 12 hr	279/2604 (11)	2/279	0.7 (0.1–2.6)	1.9 (0.3–13)		1.8 (0.3–13)	
>12 to 24 hr	161/2604 (6)	5/161	3.1 (1.0–7.1)	19 (3.1–117)		13 (2.0–86)	
>24 to 48 hr	221/2604 (8)	4/221	1.8 (0.5–4.6)	15 (2.4–90)		9.3 (1.4–62)	
>48 hr	530/2604 (20)	12/530	2.3 (1.2–3.9)	22 (4.9–103)		13 (2.6–62)	
Touched case patient's face							
No	433/2522 (17)	4/432	0.9 (0.3–2.4)	Reference			
Yes	2089/2522 (83)	28/2084	1.3 (0.9–1.9)	1.2 (0.4–4.2)	0.74	NA	
Contact with items touched by case patient							
No	1885/2602 (72)	23/1879	1.2 (0.8–1.8)	Reference			
Yes	717/2602 (28)	9/717	1.3 (0.6–2.4)	2.2 (0.9–5.8)	0.10	NA	
Contact with case patient's body fluids							
No	1656/2602 (64)	13/1652	0.8 (0.4–1.3)	Reference		Reference	
Yes	946/2602 (36)	20/944	2.1 (1.3–3.3)	7.6 (3.1–19)	<0.001	4.3 (1.6–11)	0.003
Cleaned mouth and nose of case patient after death							
No	2156/2605 (83)	26/2150	1.2 (0.8–1.8)	Reference			
Yes	449/2605 (17)	6/449	1.3 (0.5–2.9)	1.9 (0.7–5.3)	0.26	NA	



Person-to-Person Transmission during Nipah Virus Outbreaks in Bangladesh. Outbreaks in Bangladesh. Data are from Nipah virus cases identified in Bangladesh from April 2001 through April 2014. Panel A shows 17 Nipah virus person-to-person transmission trees (i.e., infection events originating from a single introduction and connected through person-to-person transmission). Squares indicate primary case patients and circles patients infected by person-to-person transmission. Blue squares and circles represent patients 25 years of age and older with difficulty breathing, a combination of characteristics that can help to identify patients who are likely to transmit Nipah virus. Alternative transmission scenarios for patients with two potential infectors are presented by red arrows. One patient (indicated by the yellow arrow) was probably infected by 1 of the 11 patients with secondary cases in the cluster, although exposure to other cases than the index case (who was excluded as infector) was not reported; 148 cases were not linked to any person-to-person transmission tree and are not represented here. Panel B shows the distribution of Nipah virus transmission trees according to the size of the tree, and Panel C shows the distribution of the number of secondary cases per Nipah virus case. Three secondary cases with multiple potential infectors were excluded. The inset shows a portion of the same data, beginning with the number of secondary cases among case patients who infected at least one other person, on an expanded y axis. Panel D shows the distribution of the serial interval (the time between symptom onset in an infector to symptom onset in a patient with an epidemiologically-linked secondary case). Three secondary cases with multiple potential infectors were excluded.



Risk Factors Associated with the Reproduction Number.

Panel A shows the predicted reproduction number according to age intervals for Nipah virus case patients with difficulty breathing. Reproduction numbers with 95% confidence intervals (indicated by the I bars) were estimated with the use of a multivariable negative binomial regression model that included age and difficulty breathing. Panel B shows the age-adjusted relative infectivity (i.e., the ratio between reproduction numbers) of case patients without difficulty breathing as compared with case patients with difficulty breathing. Panel C shows the observed reproduction number (empirical mean) according to age intervals and predictions based on the negative binomial regression model that included age and difficulty breathing. Prediction 95% confidence intervals were obtained with the use of the bootstrap method (2000 iterations).



Risk Factors Associated with Infection among Contacts of Nipah Virus Case Patients.

Data include contacts identified from January 2007 through April 2014. Panel A shows the duration of exposure among contacts who became infected and those who did not. In Panel A, the horizontal line represents the median, the top and bottom of the boxes represent the quartiles, and the I bars represent the range excluding outliers. Panel B shows observed percentage of contacts who became infected, according to the duration of exposure. The 95% confidence intervals of percentages were estimated by the Clopper–Pearson exact method. The I bars in Panels B, C, and D represent the 95% confidence intervals. Panel C shows the adjusted odds ratio of Nipah virus infection among contacts with various exposure durations as compared with contacts exposed for 1 hour or less (reference). Estimates were obtained on the basis of a multivariable logistic regression model that included the duration of exposure and exposure to body fluids as covariates and a random intercept per case. Panel D shows the adjusted odds ratio of Nipah virus infection among contacts exposed to case patients' body fluids as compared with contacts not exposed to body fluids.

Discussion

Using data from 14 years of outbreak investigations and 8 years of contact studies, we showed that Nipah virus infections among case contacts resulted in overt disease, with no evidence of asymptomatic infection, and that the risk of infection was higher among persons who had longer contact with case patients and those who were exposed to body fluids. We also found that the number of secondary infections was associated with the age of the patients infected with Nipah virus but not with the total number of contacts. In addition, our study is consistent with previous findings linking Nipah virus transmission to increased respiratory symptoms.

The risk of infection was highest among spouses and persons who had intense and longer exposure to infected persons and were probably the principal caregivers. Health care workers rarely acquired infection from a patient, probably owing to limited intensity of exposure. As the health care system in Bangladesh develops, increasing involvement of health care workers in direct patient care may increase the risk of infection.

Our study provides evidence that asymptomatic and mild Nipah virus infections are rare. Thus, estimates of the reproduction number and risk factors of infection and transmission probably can focus on symptomatic cases.

Bangladesh is the only country reporting Nipah virus outbreaks regularly, with 79 reported spillover events from April 2001 through April 2014, and our study includes all but three known outbreaks of Nipah virus with person-to-person transmission.

This study highlights patient characteristics and contact behaviors that may be related to Nipah virus person-to-person transmission. Interventions should aim to reduce exposure to body fluids, particularly oral secretions, and target prevention strategies for persons who have sustained contact with infected patients.

Progesterone Support During Pregnancy

Progesterone support in pregnancy has been in use for nearly 60 years, having received its start with publications dating back to the 1940s. Its initial use was in patients who had habitual spontaneous abortion caused by luteal phase deficiency. Luteal phase deficiency is due to a failure of the function of the corpus luteum in the production of progesterone from the corpus luteum is indispensable during the first seven weeks of pregnancy. Surgical removal of the corpus luteum during this period of time results in pregnancy loss and progesterone replacement can help maintain the pregnancy. There is evidence of support in the concept that progesterone given in early pregnancy may be useful in some women with recurrent miscarriage and that the measurement of serum progesterone levels in early pregnancy can be an adjunctive marker for the further assessment of pathologic pregnancies.



A Randomized Trial of Progesterone in Women with Bleeding in Early Pregnancy

Bleeding in early pregnancy is strongly associated with pregnancy loss. Progesterone is essential for the maintenance of pregnancy. Several small trials have suggested that progesterone therapy may improve pregnancy outcomes in women who have bleeding in early pregnancy. We conducted a multicenter, randomized, double-blind, placebo-controlled trial to evaluate progesterone, as compared with placebo, in women with vaginal bleeding in early pregnancy. Women were randomly assigned to receive vaginal suppositories containing either 400 mg of progesterone or matching placebo twice daily, from the time at which they presented with bleeding through 16 weeks of gestation. The primary outcome was the birth of a live-born baby after at least 34 weeks of gestation. The primary analysis was performed in all participants for whom data on the primary outcome were available. A sensitivity analysis of the primary outcome that included all the participants was performed with the use of multiple imputation to account for missing data.

Miscarriage affects one in five pregnancies. Miscarriage can cause excessive bleeding, infection, and complications associated with surgical treatment, as well as substantial psychological harm, including anxiety, depression, and post-traumatic stress disorder.

Characteristic	Progesterone (N = 2079)	Placebo (N = 2074)
Demographic characteristics		
Maternal age†		
Mean — yr	30.6±5.1	30.5±5.1
Distribution — no. (%)		
<35 yr	1604 (77)	1601 (77)
≥35 yr	475 (23)	473 (23)
Body-mass index†		
Mean	26.4±6.2	26.5±6.3
Distribution — no. (%)		
<30	1589 (76)	1589 (77)
≥30	490 (24)	485 (23)
Race — no. (%)‡		
White	1714 (82)	1742 (84)
Black	84 (4)	79 (4)
South Asian	114 (5)	102 (5)
Other	167 (8)	151 (7)
Pregnancy history		
Nulliparous — no. (%)	474 (23)	514 (25)
Previous preterm births at ≥24 wk to <34 wk — no. (%)	83 (4)	90 (4)
Previous miscarriages at <24 wk of gestation — no. (%)		
0	1145 (55)	1157 (56)
1 or 2	792 (38)	758 (37)
≥3	142 (7)	159 (8)
No. of previous miscarriages — median (IQR)	0 (0–1)	0 (0–1)
Amount of bleeding as assessed by PBAC score†§ — no. (%)		
≤2	1913 (92)	1907 (92)
≥3	166 (8)	167 (8)
Fetal heart activity at presentation — no. (%)†¶	1710 (82)	1701 (82)

Primary Outcome and Secondary Outcomes.

Outcome	Progesterone (N=2025)	Placebo (N=2013)	Relative Rate or Mean Difference (95% CI)†
Primary outcome — no. (%)			
Live birth at ≥34 wk	1513 (75)	1459 (72)	1.03 (1.00 to 1.07)‡
Secondary maternal outcomes — no. (%)§			
Ongoing pregnancy at 12 wk	1672 (83)	1602 (80)	1.04 (1.01 to 1.07)
Miscarriage, defined as loss of pregnancy at <24 wk¶	410 (20)	451 (22)	0.91 (0.81 to 1.01)
Live birth at <34 wk	68 (3)	64 (3)	1.06 (0.76 to 1.49)
Ectopic pregnancy	0	2 (<1)	—
Stillbirth, defined as intrauterine death at ≥24 wk	5 (<1)	6 (<1)	0.82 (0.25 to 2.66)
Termination of pregnancy‖	34 (2)	36 (2)	0.94 (0.59 to 1.50)
Secondary neonatal outcomes among women with live births at ≥24 wk§			
Gestational age at delivery**			
Wk of gestation	38 wk 4 days±2 wk 4 days	38 wk 4 days±2 wk 3 days	0.11 days (−0 wk 1 day to 0 wk 2 days)†
No. of women	1581	1521	
Birth weight††			
Mean weight — g	3242±656	3261±659	−21 (−67 to 25)†
No. of infants	1604	1539	
Death at 28 days of neonatal life — no./total no. (%)‡‡	8/1605 (<1)	2/1533 (<1)	3.84 (0.80 to 18.40)†


Subgroup
Placebo
Progesterone
no. of events/total no.
Risk Ratio (95% CI)
P Value for Interaction
Maternal age 0.70
<35 yr 1148/1555 1184/1558 1.03 (0.99–1.07)
≥35 yr 311/458 329/467 1.05 (0.97–1.13)
Body-mass index 0.31
<30 1128/1541 1155/1548 1.02 (0.98–1.06)
≥30 331/472 358/477 1.07 (0.99–1.15)
Fetal heart activity 0.37
Present 1304/1648 1347/1672 1.02 (0.99–1.06)
Absent 155/365 166/353 1.10 (0.94–1.30)
Estimated gestation at presentation 0.13
<6 wk 202/365 209/358 1.04 (0.91–1.18)
6 wk to <9 wk 832/1162 917/1211 1.05 (1.01–1.10)
≥9 wk 425/486 387/456 0.98 (0.94–1.03)
Amount of bleeding on PBAC 0.61
≤2 1344/1853 1396/1860 1.03 (1.00–1.07)
≥3 115/160 117/165 1.00 (0.88–1.14)
No. of previous miscarriages 0.007
0 840/1127 824/1111 0.99 (0.95–1.04)
1–2 534/738 591/777 1.05 (1.00–1.12)
≥3 85/148 98/137 1.28 (1.08–1.51)
No. of gestational sacs 0.34
1 1432/1975 1480/1971 1.04 (1.00–1.07)
≥2 27/38 33/54 0.90 (0.69–1.19)
Race 0.87
White 1245/1697 1263/1673 1.03 (1.00–1.07)
Black 46/75 58/82 1.08 (0.87–1.35)
South Asian 69/101 76/113 0.97 (0.82–1.15)
Other 99/140 116/157 1.04 (0.91–1.19)
History of polycystic ovaries 0.35
Yes 161/221 157/220 0.98 (0.88–1.10)
No 1297/1791 1356/1805 1.04 (1.00–1.08)
Previous LLETZ 0.30
Yes 68/102 80/109 1.12 (0.95–1.33)
No 1391/1911 1433/1916 1.03 (0.99–1.06)
All Participants 1459/2013 1513/2025 1.03 (1.00–1.07)
0.75
1.00
1.25
Placebo Better
Progesterone Better

Discussion

Our large multicenter, randomized, double-blind, placebo-controlled trial showed that among women with bleeding in early pregnancy, progesterone therapy administered during the first trimester of pregnancy did not result in a significantly higher incidence of live births after at least 34 weeks of gestation than placebo. There was also no significant difference between the groups in the incidence of miscarriage or stillbirth. Although there appeared to be slightly more ongoing pregnancies at 12 weeks in the progesterone group than in the placebo group, an inference of benefit cannot be drawn because the confidence interval for the relative rate was not adjusted for multiplicity of testing.

The large sample size in our trial allowed investigation of the primary outcome in prespecified subgroups. Among the 10 subgroup analyses, 1 showed differential effects of progesterone: the effect of progesterone in women with bleeding in early pregnancy differed according to the number of previous miscarriages, with a suggestion of benefit among women who had had three or more previous miscarriages. Previous reports have indicated a steep and proportionate increase in the loss of chromosomally normal pregnancies (i.e., euploid miscarriages) with increasing number of previous miscarriages. Given that the potential benefit of progesterone therapy would be expected to be specific to euploid pregnancies, an increasing level of benefit in women with increasing number of previous miscarriages is consistent with our understanding of the biologic factors associated with risk of miscarriage. A history of miscarriage is one of only two stratification or prognostic risk factors (the other being maternal age) cited in the 2017 guideline of the European Society of Human Reproduction and Embryology on recurrent pregnancy loss as being useful for identifying high-risk patients. However, we did not identify this subgroup as one of special interest a priori in our statistical analysis plan, and multiple comparisons were performed (without adjustment for multiplicity); thus, this observation requires validation.

In conclusion, treatment with progesterone did not result in significant improvement in the incidence of live births among women with vaginal bleeding during the first 12 weeks of pregnancy.

Progesterone for Threatened Abortion

Threatened abortion is defined as bleeding through the vagina, with a closed cervix, that occurs before the gestational age at which a fetus would be viable ex utero. Beyond this simple definition, some investigators have used additional criteria, such as confirmation that the source of the bleeding is from within the uterus and not from the cervix or vagina or requiring that the bleeding be more than mere "spotting." It is not surprising, then, that estimates of the incidence of threatened abortion vary considerably, with an incidence of approximately 25% being a reasonable contemporary estimate. For similar reasons, the estimate of the percentage of threatened abortions that progress to pregnancy loss has varied from 10% to 20% or more. Thus, most women who have bleeding in early pregnancy do not lose their pregnancies. But of course there is justifiable interest in identifying a treatment that can improve the chance of the birth of a live-born healthy baby among pregnancies at substantial risk of loss. In 1956, the Food and Drug Administration (FDA) approved hydroxyprogesterone caproate (Delalutin) for the treatment of multiple indications, including threatened abortion, which made it even more difficult not to treat women who were at risk for abortion.

In retrospect, it is likely that the initial rationale for hormonal therapy — that is, the observed fall in pregnancy hormone levels before pregnancy loss — was, in fact, a consequence rather than a cause of pregnancy failure. The subsequent enthusiasm for hormonal therapy was driven by overestimation of the incidence of pregnancy loss in the absence of therapy and by reports of seeming success in uncontrolled case series. The current randomized, placebo-controlled trial of treatment for threatened abortion provides much-needed information regarding both the true risk of pregnancy loss in the absence of treatment and the small, statistically insignificant difference in the incidence of live births between treatment and expectant management in a contemporary context.

Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers

Ticagrelor is an oral $P2Y_{12}$ inhibitor that is used with aspirin to reduce the risk of ischemic events among patients with acute coronary syndromes or previous myocardial infarction. Spontaneous major bleeding and bleeding associated with urgent invasive procedures are concerns with ticagrelor, as with other antiplatelet drugs. The antiplatelet effects of ticagrelor cannot be reversed with platelet transfusion. A rapid-acting reversal agent would be useful. In this randomized, double-blind, placebo-controlled, phase 1 trial, we evaluated intravenous PB2452, a monoclonal antibody fragment that binds ticagrelor with high affinity, as a ticagrelor reversal agent. We assessed platelet function in healthy volunteers before and after 48 hours of ticagrelor pretreatment and again after the administration of PB2452 or placebo. Platelet function was assessed with the use of light transmission aggregometry, a point-of-care $P2Y_{12}$ platelet-reactivity test, and a vasodilator-stimulated phosphoprotein assay. The primary efficacy outcome was reversal of the antiplatelet effects of ticagrelor as assessed by analysis of platelet aggregation with the use of light transmission aggregometry at multiple time points before and after the administration of PB2452 or placebo in volunteers who were pretreated with ticagrelor.

Characteristic	Placebo (N=16)	PB2452 (N=48)
Age — yr	34.0±8.3	30.5±8.8
Sex — no. (%)		
Male	11 (69)	23 (48)
Female	5 (31)	25 (52)
Weight — kg	86.2±13.5	78.2±14.8
Height — cm	173.3±6.4	167.8±10.2
Body-mass index†	28.6±3.3	27.7±4.1
Race or ethnic group — no. (%)‡		
White	7 (44)	27 (56)
Black	8 (50)	18 (38)
Asian	0	1 (2)
American Indian or Alaska Native	1 (6)	0
Native Hawaiian or Pacific Islander	0	1 (2)
Multiple	0	1 (2)
Hispanic ethnic group — no. (%)‡		
Hispanic	6 (38)	22 (46)
Not Hispanic	10 (62)	26 (54)
Platelet count per mm^3	239,000±52,100	253,000±46,800
Platelet aggregation on light transmission aggregometry — %§	82.1±7.5	82.9±7.5
Platelet reactivity units on point-of-care $P2Y_{12}$ platelet-reactivity test¶	226.4±39.9	237.7±36.8
Platelet reactivity index on VASP assay‖	89.8±4.2	90.2±3.6

Currently, no reversal agents for $P2Y_{12}$ receptor antagonists are known. Unlike the other $P2Y_{12}$ receptor antagonists, ticagrelor is a reversible inhibitor, which makes the development of a specific reversal agent for ticagrelor feasible. PB2452 (formerly MEDI2452) is a neutralizing monoclonal antibody fragment that binds ticagrelor and its major active circulating metabolite with high affinity.

A total of 30 adverse events that occurred after initiation of PB2452 or placebo were reported by 19 of the 64 volunteers (30%). Of the 48 volunteers who received PB2452, 17 (35%) reported 27 adverse events; of the 16 volunteers who received placebo, 2 (12%) reported 3 adverse events. There were no dose-limiting toxic effects or infusion-related reactions. There were no deaths or adverse events that led to discontinuation of the trial drug or hospitalization. One volunteer had 2 serious adverse events (alcohol poisoning and acute respiratory failure) 4 days after discharge from the clinical site. Except for 2 volunteers, in cohorts 1 and 3, all volunteers with adverse events had received ticagrelor pretreatment. Changes in mean clinical laboratory test results, vital signs, and electrocardiographic results were similar across cohorts among volunteers who received different doses or regimens of PB2452 and were similar among those who received PB2452 and those who received placebo.

Table 2. Adverse Events.*

Variable	Placebo (N=16)	PB2452 (N=48)
Any event — no.	3	27
Volunteers with event — no. (%)†	2 (12)	17 (35)
Bruising at infusion site	0	4 (8)
Reaction at medical device site	0	3 (6)
Bruising at vessel puncture site	0	2 (4)
Extravasation at infusion site	0	2 (4)
Abdominal pain	0	1 (2)
Acute respiratory failure	0	1 (2)
Alcohol poisoning	0	1 (2)
Aspiration pneumonia	0	1 (2)
Blood in urine	0	1 (2)
Conjunctivitis	0	1 (2)
Contusion	1 (6)	0
Dizziness	0	1 (2)
Eyelid irritation	1 (6)	0
Gastroenteritis	0	1 (2)
Hematuria	0	1 (2)
Musculoskeletal chest pain	1 (6)	0
Nasopharyngitis	0	1 (2)
Oropharyngeal pain	0	1 (2)
Reaction at infusion site	0	1 (2)
Skin abrasion	0	1 (2)
Streptococcal pharyngitis	0	1 (2)
Upper limb fracture	0	1 (2)

* Shown are adverse events that occurred after initiation of PB2452 or placebo. The terms are based on codes from the *Medical Dictionary for Regulatory Activities*, version 21.0.

† For each entry, a volunteer is counted once if he or she reported one or more events.

Onset and Duration of Ticagrelor Reversal. Ticagrelor reversal is shown as an increase in mean platelet aggregation after ticagrelor pretreatment, as assessed with the use of light transmission aggregometry. Shown are the onset and duration of ticagrelor reversal among volunteers in cohorts 4, 5, and 6, who were randomly assigned to receive either a 30-minute infusion of PB2452 at a dose of 1 g, 3 g, and 9 g, respectively, or placebo (Panel A), as well as among volunteers in cohorts 7, 8, 9, and 10, who were randomly assigned to receive an 18-g fixed dose of PB2452 with an infusion duration of 8 hours, 12 hours, 16 hours, and 16 hours, respectively, or placebo (Panel B). Mean platelet aggregation at baseline (before the administration of ticagrelor) is shown at −48 hours. P values are for the comparison of PB2452 with placebo. Statistical testing was not performed in cohort 9 because only three volunteers in that cohort received PB2452. I bars indicate the standard deviation. NA denotes not available.



P Values at Time Point:	0.5 Hr	1 Hr	2 Hr	3 Hr	6 Hr	12 Hr	24 Hr	48 Hr
Cohort 4	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Cohort 5	0.02	1.00	1.00	0.15	1.00	1.00	1.00	1.00
Cohort 6	0.02	0.04	0.04	0.09	1.00	1.00	0.58	1.00

P Values at Time Point:	5 Min	0.25 Hr	0.5 Hr	1 Hr	2 Hr	3 Hr	6 Hr	8 Hr	10 Hr	12 Hr	16 Hr	20 Hr
Cohort 7	0.04	0.04	0.13	0.04	0.40	0.02	0.02	0.02	0.15	0.02	0.02	0.22
Cohort 8	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.15	0.02	0.02	0.02
Cohort 10	0.04	0.02	0.02	0.02	0.02	0.02	0.02	0.02	NA	0.02	0.02	0.02



Normalization of Platelet Function after Ticagrelor Reversal. Normalization of platelet function is shown as an increase in platelet function to within the normal range after ticagrelor pretreatment and subsequent initiation of PB2452. Shown are data from cohorts 9 and 10 (pooled). On light transmission aggregometry (Panel A), a normal level of platelet aggregation is at least 80% of the baseline value (dashed line). On the point-of-care $P2Y_{12}$ platelet-reactivity test (Panel B), a normal level of platelet reactivity units is at least 180 (dashed line). On assessment of $P2Y_{12}$ receptor signaling with the vasodilator-stimulated phosphoprotein (VASP) assay (Panel C), a normal platelet reactivity index is at least 80% of the baseline value (dashed line). Red diamonds indicate the mean, horizontal lines the median, and I bars the range. The tops and bottoms of the boxes indicate the third and first quartiles, respectively.

Discussion

In this trial, intravenous infusion of the monoclonal antibody fragment PB2452 significantly reversed the antiplatelet effects of ticagrelor, as measured by multiple assays of platelet function. In the healthy trial population, there were no serious adverse events or infusion-related reactions that were determined to be associated with PB2452. It remains unclear whether reversal of the antiplatelet effects of ticagrelor by PB2452 would lead to more rapid hemostasis in patients with bleeding or to prevention of bleeding in patients who are undergoing urgent invasive procedures.

PB2452 is a recombinant human IgG1 monoclonal antibody antigen-binding fragment that binds with high affinity and specificity to rapidly neutralize ticagrelor and its active metabolite AR-C124910XX. The high affinity and specificity of PB2452 enables it to neutralize free ticagrelor and prevent binding to the $P2Y_{12}$ receptor. These properties explain the immediate reversal that was observed with PB2452, and such reversal is a key feature for patients with hemorrhage. The mechanism of action is expected to be specific to ticagrelor and not work with clopidogrel or prasugrel, which are irreversible $P2Y_{12}$ receptor antagonists.

In conclusion, we found that the administration of intravenous PB2452 reversed the antiplatelet effects of ticagrelor, as measured by multiple assays of platelet function, and was associated with minimal low-grade toxic effects.



Ticagrelor ist ein Thrombozytenaggregationshemmer, der die Verklebung der Blutplättchen und so die Bildung von Blutgerinnseln hemmt. Er wird zur Verhinderung eines Herzinfarkts eingesetzt. Der Wirkstoff ist seit 2010 in der Europäischen Union und 2011 in den Vereinigten Staaten zugelassen. Jahres Kosten €1092, Clopidogrel €32.

MicroRNA, abgekürzt miRNA oder miR, sind kurze, hoch konservierte, nichtcodierende RNAs, die eine wichtige Rolle in dem komplexen Netzwerk der Genregulation, insbesondere beim Gen-Silencing spielen. MicroRNAs regulieren die Genexpression hochspezifisch auf der post-transkriptionalen Ebene. Im Allgemeinen weisen microRNAs eine Größe von 21 bis 23 Nukleotiden (nt) auf, doch können es auch einige Hundert sein (siehe Abbildung).

Die Genregulation erfolgt bei Tieren durch Bindung der microRNAs an die 3’ untranslatierte Region (3’-UTR) der mRNA von Zielgenen, welche je nach Komplementarität der Bindesequenz und der beteiligten Proteine entweder an der Translation gehemmt, oder durch Zerschneiden abgebaut werden. Partielle Komplementarität führt zur Translationshemmung, während perfekte Basenpaarung zur Degradation der Ziel-mRNA führt. Während lange Zeit davon ausgegangen wurde, dass von diesen beiden Mechanismen die Translationshemmung dominiert, ergaben neuere Studien, dass die Degradation von Ziel-mRNA relativ gesehen für einen größeren Anteil der Inhibition der Proteinproduktion verantwortlich ist.

Die RNase III (Drosha) und das dsRNA-Bindeprotein DGCR8 (entspricht Pasha bei Drosophila melanogaster) formen einen Mikroprozessor-Komplex. Dicer interagiert mit dem ds-RNA-Bindeprotein TRBP (RDE-4 in *C. elegans* und Loquacious in *Drosophila melanogaster*), wodurch die miRNA-Duplex entwunden und einzelsträngig wird. Dabei wird an dem Ende mit der geringeren thermodynamischen Stabilität begonnen. Abhängig davon bildet der miRNA-Strang mit dem 5’ Terminus an seinem Ende die reife miRNA, die auch guide RNA genannt wird.







Dicer (**wörtlich etwa „Würfelschneider“,** von engl.: to dice: „in Würfel schneiden“) ist eine Endoribonuklease, die doppelsträngige RNA in kurze, doppelsträngige Fragmente schneidet. Je nach Substrat werden diese Produkte unterschiedlich bezeichnet. Diese Fragmente sind etwa 20 bis 25 Nukleotide lang und spielen bei dem Mechanismus der RNA-Interferenz die zentrale Rolle. Mutationen im DICER1-Gen sind assoziiert mit frühkindlichem Tumor (Pleuro-pulmonales Blastom) und mehrknotiger Struma.
Dicer ist ein RNase-III-ähnliches Enzym. Es enthält zwei RNase-III-Domänen und eine PAZ-Domäne. Der Abstand zwischen diesen beiden Domänen wird durch einen Helixbereich bestimmt, dessen Länge die Länge der entstehenden siRNAs bestimmt. Dicer katalysiert den ersten Schritt der RNA-Interferenz und initiiert die Bildung des RNA-induced silencing complex (RISC), dessen Endonuklease „argonaute“ in der Lage ist, mRNA abzubauen, deren Sequenz komplementär zu der entstandenen siRNA ist.
Mithilfe von Knockout-Moosen konnte gezeigt werden, dass DCL1b, eines von vier Dicer-Proteinen von Physcomitrella, nicht für die miRNA Biogenese, sondern für das Schneiden der Zieltranskripte notwendig ist. Dies führte zur Aufklärung eines neuen Mechanismus der Genregulation.
Der Name Dicer wurde von Emily Bernstein vergeben, einer Doktorandin in der Arbeitsgruppe von Greg Hannon am Cold Spring Harbor Laboratory, die als erste Ribonuklease-Aktivität des Dicers an dsRNA zeigen konnte.



Dicer1 Syndrom: Der Würfelschneider: Klinische Symptomatik

Keimbahnmutationen in *DICER1* verursachen ein seltenes autosomal-erbliches Tumorsyndrom (auch als DICER1-Syndrom bezeichnet). Die Betroffenen haben insbesondere ein erhöhtes Risiko für Tumore im Kindes- und jungen Erwachsenenalter. Die Penetranz des Syndroms ist jedoch nicht vollständig. Es gibt Hinweise, dass nur bis zu 50 % der weiblichen Anlageträger eine Tumorerkrankung entwickeln, männliche Anlageträger sogar in einem noch geringeren Anteil. Aufgrund der Seltenheit des Syndroms und der damit verbundenen geringen Zahl bekannter Familien sind konkrete Angaben hierzu jedoch sehr schwierig.

Das DICER1-Syndrom geht insbesondere mit einem erhöhten Risiko für Pleuropulmonale Blastome des Kindesalters, Zystische Nephrome der Niere, ovarielle Keimstrang-Tumoren (insbesondere Sertoli-Leydig-Zell-Tumoren), Schilddrüsentumoren (meist gutartige Struma multinodosa, selten auch Karzinome) und embryonale Rhabdomyosarkome (vor allem der Niere, der Vagina und der Cervix uteri) einher. Daneben sind eine Vielzahl weiterer Tumoren in Einzelfällen in Zusammenhang mit dem Syndrom beschrieben, so dass das weitere Tumorspektrum nur schwer zu definieren ist.





Mesenchymal Hamartoma of the Liver and DICER1 Syndrome

Mesenchymal hamartoma of the liver (MHL) is a benign tumor affecting children that is characterized by a primitive myxoid stroma with cystically dilated bile ducts. Alterations involving chromosome 19q13 are a recurrent underlying cause of MHL; these alterations activate the chromosome 19 microRNA cluster (C19MC). Other cases remain unexplained. We describe two children with MHLs that harbored germline *DICER1* pathogenic variants. Analysis of tumor tissue from one of the children revealed two *DICER1* "hits." Mutations in *DICER1* dysregulate microRNAs, mimicking the effect of the activation of C19MC. Our data suggest that MHL is a new phenotype of DICER1 syndrome.

Aberrant activation of the chromosome 19 microRNA cluster (C19MC), leading to dysregulated microRNA profiles, is often implicated in MHL. Located on chromosome 19q13.4, C19MC encodes a paternally imprinted cluster of 46 primate-specific microRNAs expressed in placenta and also in certain cancers. This microRNA alteration in MHL results from either androgenetic–biparental mosaicism (in which a subset of the person's cells has complete paternal uniparental disomy and the rest of the cells have one set of chromosomes derived from the mother and one from the father) or chromosomal rearrangements in the 19q13.4 region.



A plus sign indicates a person who is heterozygous for a *DICER1* pathogenic germline variant, and a minus sign indicates a person with wild-type *DICER1*.



DICER1 Testing, In Vitro Cleavage Assays, and MicroRNA Expression. Shown are sample chromatograms of *DICER1* genotypes in germline and tumor DNA obtained from Child 1 (Panel A) and Child 2 (Panel B). Sites of mutation or loss of heterozygosity are indicated by asterisks. Panels C and D show the results of in vitro cleavage assays for DICER1 proteins with the use of the precursor microRNA 122 (pre-miR-122) hairpin: DICER1 p.E1705Q in Child 1 and DICER1 p.N1742del in Child 2. DICER1 p.D1709Y was used as the hot-spot mutation–positive control. The pre-miR-122 hairpin was chosen because miR-122 is critically implicated in liver development. The expected pattern of cleavage is shown in wild-type (WT) DICER1, with increasing cleavage of the pre-miR-122 hairpin (marked with an asterisk) occurring over a period of 120 minutes, leading to a diminution of the intensity of the pre-miR-122 band at 60 nucleotides and increasing intensity of both 3p (bottom band, shown as gray arrow) and 5p (top band, black arrow) over the same period. Both DICER1 p.E1705Q and DICER1 p.N1742del showed aberrant patterns with production of an uncleaved 5p arm (red arrow, band at 40 nucleotides) and less 5p and 3p products, with the decrease of 5p being more pronounced. radiolabeled RNA molecular-weight marker (M) was loaded in every assay. Panel E shows histograms of the relative levels of expression of four microRNAs measured by quantitative polymerase-chain-reaction (PCR) assay in two MHL samples from Child 1 (MHL from the first surgery and MHL′ from the second surgery), normal liver samples (N1, N2, and N3) from three separate persons, and an MHL with activation of the chromosome 19 microRNA cluster (C19MC) and no *DICER1* mutations (C19MC MHL). MHL samples from Child 1 showed altered microRNA expression as compared with C19MC MHL.



Chromosome 19q13 and C19MC MicroRNA Expression in Child 1's MHL. Panel A shows the results of an OncoScan single-nucleotide polymorphism (SNP) array for chromosome 19q13 in a sample of MHL obtained during Child 1's first surgery, with the $\log_2$ ratio shown at the top and the B-allele frequency (BAF) shown at the bottom. On chromosome 19q13, neither copy-number alterations nor a copy-neutral loss of heterozygosity was detected. The C19MC region is marked with a red rectangle. Panel B shows representative interphase nuclei of Child 1's MHL from the first surgery that was hybridized with the 19q13 break-apart fluorescence in situ hybridization (FISH) probe. Interphase cells show two green–red fusion (yellow) signals, indicating no break in chromosomal region 19q13. The inset shows one interphase nuclei in detail. Owing to sectioning artifacts, some signals may be missing. Panel C shows histograms of the relative levels of C19MC microRNA expression measured by quantitative PCR assay in two MHL samples from Child 1 (MHL from the first surgery and MHL′ from the second surgery), normal liver samples (N1, N2, and N3) from three separate persons, and an MHL with C19MC activation (C19MC MHL). MHL samples from Child 1 had lower microRNA expression than the positive MHL. The standard deviations of the cycle thresholds are plotted as I bars.

Discussion

In this report, we describe a child with MHL that lacked tumor C19MC (a microRNA cluster of 46 genes encoding 59 microRNAs) activation but instead harbored a germline truncating pathogenic variant and a somatic hot-spot mutation in *DICER1*. We describe a second child with a liver lesion consistent with MHL, several phenotypes associated with DICER1 syndrome, and a pathogenic germline *DICER1* variant. We previously reported a four-amino-acid deletion resulting in a similar protein change (p.N1741_1744del) in a child with cystic nephroma, multinodular goiter, and a lung cyst, all of which were present in Child 2. Our data suggest that MHL can also be caused by *DICER1* mutations and is a phenotype of DICER1 syndrome. In Child 1's MHL, from which we had sufficient tissue for analysis, we found neither chromosomal translocations nor androgenetic–biparental mosaicism and no activation of five C19MC microRNAs, findings that ruled out the recognized causes of MHL. We also observed that in Child 1's MHL the expression of certain liver-expressed microRNAs was altered, presumably because of the two *DICER1* mutations. Specifically, miR-122, a microRNA critically implicated in hepatocyte maturation and differentiation, was significantly down-regulated as compared with the normal liver tissues and with a non-*DICER1* MHL with C19MC expression.

In Child 1's MHL, from which we had sufficient tissue for analysis, we found neither chromosomal translocations nor androgenetic–biparental mosaicism and no activation of five C19MC microRNAs, findings that ruled out the recognized causes of MHL. We also observed that in Child 1's MHL the expression of certain liver-expressed microRNAs was altered, presumably because of the two *DICER1* mutations. Specifically, miR-122, a microRNA critically implicated in hepatocyte maturation and differentiation, was significantly down-regulated as compared with the normal liver tissues and with a non-*DICER1* MHL with C19MC expression.

The relationship between MHL and its malignant counterpart, undifferentiated embryonal sarcoma, resembles that seen between the subtypes of pleuropulmonary blastoma. Type I pleuropulmonary blastoma consists of primitive mesenchymal cells and cysts, and sarcomatous overgrowth of the cysts by the primitive cells leads to solid tumor formation (types II and III pleuropulmonary blastoma).

Die Balkan-Nephropathie,

auch Danubian endemic familial nephropathy (DEFN), eine Form der interstitiellen Nephritis, ist eine Nierenerkrankung, die chronisch verläuft und schließlich zu einer tödlichen Niereninsuffizienz führt. Der sonst meist mit Nierenerkrankungen einhergehende Bluthochdruck fehlt hier zunächst. Die Erkrankung tritt endemisch (ausschließlich) in einigen ländlichen Regionen des Donautales und dessen Seitentälern im Balkan auf, und zwar in Bosnien, Bulgarien, Kroatien, Rumänien und Serbien. Die Ursache der erstmals Mitte der 1950er Jahre beschriebenen und 1956 in den ICD formell anerkannten Erkrankung war trotz intensiver Untersuchungen jahrzehntelang unklar. Man vermutete unter anderem Schimmelpilzgifte (Mykotoxine), pflanzliche Arzneimittel der Volksmedizin (Phytotoxine), Schwermetalle, Viren oder Mangel an Spurenelementen.
Mitte 2007 wurden Forschungsergebnisse eines Teams der US-amerikanischen Stony Brook University veröffentlicht, die der Hauptursache auf die Spur kamen. Ursächlich ist demnach vor allem eine Vergiftung durch mehrjährigen Verzehr von Brot, dessen Mehl aus mit Aristolochiasäuren verunreinigtem Weizen der Region gemahlen wurde. Die Verunreinigung des Getreides rührt von Samen der Gewöhnlichen Osterluzei (Aristolochia clematitis, auch Biberkraut genannt) her, einem in dieser Region nicht seltenen Ackerunkraut. Die relativ armen Bauern in dieser Region konnten das Unkraut in den Getreidefeldern bisher nicht dezimieren, da sie sich keine teuren Herbizide leisten können. Ein ernst zu nehmendes Risiko des Auftretens einer Nephropathie besteht bei rund 100.000 Menschen der betroffenen Balkanregion. Glyphosat schützt vor Balkan-Nephropathie.
Mit der Balkan-Nephropathie geht häufig auch eine ansonsten seltene Krebserkrankung des Urothelgewebes der oberen Harnwege einher. Stoffwechselprodukte des Biberkrauts binden sich an die DNA und lösen dort Mutationen unter anderem am Tumorsuppressorprotein p53 aus, so dass dessen Funktion im menschlichen Tumorschutzsystem beeinträchtigt wird.



Der biochemische Mechanismus der Mutagenität der Aristolochiasäuren beruht auf einer Transversion von A-T-Nukleotidpaaren nach T-A an verschiedenen Stellen im Genom.

Chronic Kidney Disease of Unknown Cause in Agricultural Communities

In recent years, numerous cases of chronic kidney disease have emerged among agricultural workers, as well as among others performing manual labor, in various regions of the world. The disease does not appear to be due to the classic causes of kidney disease (e.g., diabetes, hypertension, and glomerular disease). In this review, we describe the clinical presentation and epidemiology of chronic kidney disease that is endemic in this workforce in these areas, as well as possible causes. The disease is strongly associated with working and living in a hot environment, but whether the cause is a toxin, an infectious agent, a heat-associated injury, or a combination of factors is not yet known. We also discuss some of the assumptions and limitations in our understanding of chronic kidney disease in agricultural communities.

Mesoamerican Nephropathy

During the 1990s, clinicians in Central America noted that a large number of young sugarcane workers were presenting with end-stage kidney disease. An early report on an upsurge in chronic kidney disease in Central America came from El Salvador in 2002. One striking finding was that the patients, once evaluated, did not have any of the conditions known to cause end-stage kidney disease, such as diabetes, hypertension, or glomerular disease. Within a short time, multiple reports confirmed higher-than-expected rates of chronic kidney disease among sugarcane workers and other agricultural workers who were laboring in the fields along the Pacific Coast of Central America, from Guatemala to Panama, and the name Mesoamerican nephropathy was proposed for the disorder.

Sri Lankan Nephropathy

A spate of chronic kidney disease of unknown origin has also been identified in the North Central Province of Sri Lanka. The disease, which was first described in the 1990s, affects persons working in the rice paddies in rural regions. The similarities to Mesoamerican nephropathy are noteworthy, with most patients presenting with asymptomatic elevations of serum creatinine levels, low-grade or no proteinuria, and chronic interstitial nephritis with variable glomerulosclerosis in patients who undergo renal biopsy.

Uddanam Nephropathy

Numerous cases of chronic kidney disease have been reported among rural farmers in India, especially in Central India in the states of Andhra Pradesh, Odisha, Chhattisgarh, and Maharashtra. Affected patients usually present with normal blood pressure, low-grade or no proteinuria, and a relatively bland urinary sediment with occasional red cells and leukocytes. Renal biopsy, when performed, shows chronic interstitial disease.

Table 1. Demographic and Clinical Characteristics of Chronic Kidney Disease of Unknown Cause.*

Variable	Mesoamerican Nephropathy	Sri Lankan Nephropathy	Uddanam Nephropathy
Region	Pacific Coast, rural areas from Mexico to Panama	North Central Province	Central Indian states of Andhra Pradesh, Odisha, Chhattisgarh, Maharashtra
Demographic features	Age range, 20–50 yr Male:female ratio, ≥3:1	Age range, 40–50 yr Male:female ratio, 1.3:1	Age range, 30–60 yr More common in men
Affected population	Sugarcane workers, cotton workers, corn farmers, construction workers, port workers, miners, fishing industry workers, shrimp farm workers, brick workers	Rice farmers	Cashew, rice, and coconut farmers
Hypothesized causes			
Heat exposure	Low-altitude areas with hot tropical climate, physical exertion, recurrent dehydration	Low-altitude areas with hot tropical climate	Coast and inland up to 60–70 m above sea level with hot tropical climate
Other	Toxic causes: pesticides, heavy metals, NSAIDs, tobacco use Infections: leptospirosis, hantavirus infection Gene–environment interactions	Cadmium, pesticides (glyphosate), hard water, high fluoride content in drinking water, arsenic, glyphosate chelation with metals, low water intake, malaria	Silica in groundwater, excessive use of painkillers, low water intake
Clinical findings			
Acute phase	Fever, elevated serum creatinine level, muscle and joint pain, leukocytosis, leukocyturia, hematuria	Fever, fatigue, dysuria, joint pain, elevated serum creatinine level	Not described so far
Chronic phase	Insidious presentation (elevated serum creatinine level), low-grade or no proteinuria, hypokalemia, hyponatremia, hypomagnesemia, frequent hyperuricemia, reduced kidney size on ultrasound	Insidious presentation (elevated serum creatinine level), low-grade or no proteinuria, hypokalemia, hyponatremia, hypomagnesemia, frequent hyperuricemia, reduced kidney size on ultrasound	Insidious presentation (elevated serum creatinine level), low-grade or no hypertension, low-grade or no proteinuria, microscopic hematuria (rare), reduced kidney size on ultrasound

* NSAIDs denotes nonsteroidal antiinflammatory drugs.

Table 2. Hypothesized Occupational and Environmental Risk Factors for the Development or Progression of Chronic Kidney Disease (CKD).

Possible Cause	Potential Mechanisms	Positive Evidence	Negative Evidence
Heat and dehydration	Repeated intermittent injury from four processes: Heat stroke (elevated body temperature) with inflammatory response Dehydration leading to hyperosmolarity, mediated by vasopressin and polyol pathway Heat exposure and exertion, leading to repeated subclinical rhabdomyolysis Increased core temperature, leading to uricosuria or crystalluria	Heat and dehydration cause CKD in animals CKD occurs in hot regions, and symptoms of dehydration are common Acute kidney injury correlates with heat exposure and physical exertion Heat stroke may cause acute kidney injury with late chronic interstitial nephritis Hyperuricemia and urate crystalluria are common in sugarcane cutters	There is limited evidence that acute kidney injury during a work shift leads to CKD CKD has not been reported in some extremely hot regions of the world Many occupations associated with heat exposure have not been associated with an increased risk of CKD No studies have shown that preventing acute kidney injury with hydration reduces the risk of CKD Hyperuricemia is not required for CKD to develop
Pesticides: glyphosate, paraquat, 2,4-dichlorophenoxyacetic acid, atrazine, cypermethrin, organophosphates, carbamates	Uptake from urine into the proximal tubule of the kidney, with toxic effects	Pesticides are commonly used in agriculture, and some are known to be nephrotoxic; they can get into soil, crops, and groundwater The increase in Sri Lankan nephropathy in the 1990s corresponded with increasing mechanization and use of pesticides	Most studies show minimal levels of pesticides in the drinking water in affected regions No obvious signs of pesticide intoxication have been reported in association with CKD Pesticides comprise hundreds of active ingredients, and pesticide use is heterogeneous across regions and crops Besides glyphosate, no potential etiologic agent has been identified CKD has not been reported in many regions with extensive use of glyphosate or other pesticides
Heavy metals, minerals, and halides: arsenic, cadmium, lead, silica, fluoride, other (magnesium, mercury, nickel, uranium)	Uptake from urine into the proximal tubule of the kidney, with toxic effects	Many metals have known toxic effects on the kidney Silica levels are high in wells in areas affected by Uddanam nephropathy, and silica is also present in sugarcane soot and air particles; silica can cause chronic interstitial nephritis in animals	Most studies have not shown elevated concentrations of heavy metals or fluoride in groundwater; patients with CKD do not have silicosis of the lung
Infections: leptospirosis, hantavirus infection, vector-transmitted diseases (malaria, dengue)	Leptospirosis and hantavirus infection can cause acute kidney injury, leptospirosis can cause acute interstitial nephritis and fever, and malaria and dengue can cause acute kidney injury	Leptospirosis is common in rural agricultural workers, as are malaria and dengue; chronic infection from leptospirosis can lead to chronic interstitial nephritis	There is no evidence that leptospirosis or other infections are more common in patients with CKD than in those without CKD
Other: NSAIDs, tobacco smoking, sugared and phosphate-containing drinks (fructose and phosphate), alcohol (illegal alcohol), aristolochic acid, herbal remedies	Most of these are known risk factors for acute kidney disease or CKD	Some of these have been reported to be risk factors for Mesoamerican and Sri Lankan nephropathy (especially NSAIDs and tobacco)	Many persons in these regions in whom CKD develops do not have a history of NSAID or tobacco use



Possible Mechanisms for the Development of Mesoamerican Nephropathy.
One possible mechanism that has been proposed for the development of Mesoamerican nephropathy is the uptake of toxins in the tubules, resulting in direct toxicity. Another proposed mechanism is heat exposure leading to dehydration and volume depletion or an increase in core temperature, which may cause kidney injury directly through tissue dysfunction or indirectly through hyperosmolarity or rhabdomyolysis. In addition, heat-associated dehydration may also cause kidney injury by amplifying the renal effects of toxins or toxicants. It has also been proposed that infectious agents may be involved in the pathogenesis of Mesoamerican nephropathy, although this hypothesis remains unproven. For all mechanisms, genetic factors could be important.



A 59-year-old woman presented to the emergency department with a 4-day history of inflammation and pain in the right eye. She had been blind in the eye for several years before presentation. The physical examination showed proptosis of the right eye, with periorbital inflammation, ophthalmoplegia, and a right relative afferent pupillary defect. Magnetic resonance imaging revealed a right orbital mass measuring 2.8 cm by 2.5 cm by 2.3 cm with intraocular and extraocular components (Panel A). The patient's levels of alanine aminotransferase and aspartate aminotransferase were normal, but there were elevations in the alkaline phosphatase level (245 U per liter; reference range, 31 to 95) and the γ-glutamyltransferase level (225 U per liter; reference range, 7 to 37). Abdominal and thoracic imaging showed numerous hepatic masses, abdominal and thoracic lymphadenopathy, and vertebral sclerotic osseous disease, findings that were consistent with widely metastatic disease. The right eye was enucleated for palliative relief and to obtain tissue for diagnosis (Panel B). Immunohistochemical evaluation supported the diagnosis of uveal melanoma. The patient was treated with ipilimumab and nivolumab, but she died from progressive disease 2 months after presentation.

A 66-year-old man presented to the emergency department with a 2-month history of abdominal bloating and worsening constipation. His medical history was notable for untreated hypertension and hyperlipidemia. He had been an active smoker for more than 20 years, and his father had died suddenly at 62 years of age from an unknown cause. The patient's blood pressure was 162/83 mm Hg, and the physical examination revealed a painless pulsatile abdominal mass. The femoral pulses were palpable on both sides. Computed tomographic angiography revealed a large fusiform infrarenal aortic aneurysm measuring 11 cm by 10.5 cm by 14 cm. The patient underwent surgery, during which the aneurysm was exposed and replaced with an aortobiiliac graft. He also began medical treatment for hypertension and hyperlipidemia. At a 6-month follow-up visit, the patient had no pulsatile abdominal mass, had good perfusion to his legs, and felt well.

A 44-Year-Old Man with Neck Pain and Swelling

Twelve weeks earlier, at this hospital, the patient had undergone uncomplicated placement of an implantable cardioverter–defibrillator (ICD) through the left cephalic vein. Immediately after implantation, he began to have a transient sensation of “pins and needles” in the left hand; he previously had had similar, work-related tingling and decreased sensation in the ulnar-nerve distribution of the left arm. Neurologic examination was normal. A chest radiograph showed that the ICD leads were in the appropriate positions. Three weeks after implantation, routine interrogation of the ICD was normal.

Five weeks after implantation, the patient awoke with a headache and neck pain on the left side. He initially attributed the pain to his sleeping position, but it continued throughout the day. When numbness and tingling developed in the left fingertips, along with shooting pains in the left arm and toes, he presented to another hospital and was admitted for further evaluation.

At the other hospital, imaging studies were obtained. A computed tomographic (CT) scan of the head, obtained without the administration of intravenous contrast material, was normal. CT angiography of the chest and abdomen ruled out pulmonary embolism and aortic dissection but revealed a partially visible mass in the left supraclavicular region. Ultrasonography of the neck revealed a complex mass, measuring 4.3 cm in diameter, without internal Doppler flow.





Numbness and tingling in the left arm increased in intensity, and the next morning, the patient was transferred to the cardiology unit of this hospital, where he was evaluated by the neurology and vascular surgery services. Examination was notable for tenderness and firmness in the left supraclavicular fossa, without erythema or drainage, and mildly diminished pinprick sensation along the lateral dorsum of the left hand and the ophthalmic and maxillary branches of the left trigeminal nerve.

Ultrasonographically guided needle aspiration revealed 5 ml of thin, brown fluid that was suggestive of old blood, with 104,500 white cells per cubic millimeter, of which 79% were neutrophils. Gram's staining revealed few neutrophils and mononuclear cells and no organisms. An acid-fast stain for mycobacteria was negative, and microbiologic cultures were performed. Clopidogrel was stopped, and the dose of aspirin was increased. The patient was discharged after 2 days. He received a 7-day course of cephalexin, a tapering course of gabapentin, and oxycodone to be taken as needed. He was advised to avoid lifting his arm above his head.

Two weeks after discharge, at the electrophysiology clinic of this hospital, the patient reported that the neck swelling had greatly reduced but residual numbness was present in the tips of the left third, fourth, and fifth digits. Five days after the evaluation in the electrophysiology clinic, he returned to the emergency department of this hospital for recurrent swelling and pain in the neck and supraclavicular region on the left side; numbness and tingling in the face, shoulder, and arm on the left side; mild dysphagia; and a feeling that his face was hotter on the left side than on the right side. Residual numbness in the tips of the left third, fourth, and fifth digits persisted. Examination was notable for reduced sensation in the left trigeminal-nerve distribution and dysesthesia in the trigeminal-nerve distribution and left arm.

The patient was admitted to the cardiology unit. The hemoglobin level was 11.4 g per deciliter (normal range, 13.5 to 17.5), and the hematocrit 32.3% (normal range, 41 to 53). All other blood test results, including the troponin T level and results of liver-function tests, were normal, as was urinalysis. Specimens of blood were obtained for culture, and additional imaging studies were performed. Needle aspiration of the mass was again performed and revealed 1.5 ml of thick red fluid that appeared to be consistent with blood. Gram's staining revealed abundant mononuclear cells and no neutrophils or organisms. Fluid aspirate was obtained for culture. Cephalexin and gabapentin were resumed, and the patient was discharged after 2 days.

Two weeks after discharge, in the electrophysiology clinic, the patient reported resolution of the pain in the neck and arm on the left side. He had numbness in only the left third, fourth, and fifth digits. Clopidogrel was resumed.

A review of systems was notable for sciatica and heartburn. The patient had no symptoms of heart failure or dysrhythmia, fever, chills, sweats, chest pain, weight loss, appetite change, rash, or pruritus. The medical history was notable for hypertension, dyslipidemia, and coronary artery disease with two anterior ST-segment elevation myocardial infarctions. The first, which had occurred 8 years before this admission, was treated with percutaneous coronary interventions and was complicated by acute in-stent thrombosis and later in-stent restenosis. The second, which had occurred 14 months before this admission in the presence of occlusion of the previously placed stents, was treated with intraaortic balloon counterpulsation and multivessel coronary-artery bypass grafting. The patient had resultant ischemic cardiomyopathy and progressive left ventricular systolic dysfunction, with a current left ventricular ejection fraction of 28%.

In addition, the patient had a history of asthma, for which he had had multiple intubations, tapering courses of glucocorticoids, and admissions to the intensive care unit. When he was 20 years of age, he had testicular cancer, for which he received treatment with orchiectomy and chemotherapy at another hospital. He also had a history of erosive esophagitis and depression. Medications included aspirin, clopidogrel, simvastatin, carvedilol, lisinopril, gabapentin, quetiapine, and omeprazole. Heparin had caused thrombocytopenia, and various statin drugs had caused myalgias.

There was no family history of coronary artery disease or cardiomyopathy. The patient's mother had hypertension and diabetes, and his father, brother, and two children were all healthy. He was disabled and had not worked since he had his first myocardial infarction. He smoked a half pack of cigarettes per day and had done so since he was 16 years of age, and he also smoked marijuana. He had a history of binge drinking, which had been complicated by pancreatitis, as well as a history of cocaine use, but he had been abstinent from both alcohol and cocaine for the previous 3 years.

On examination, the temperature was 36.7° C, the heart rate 81 beats per minute, the blood pressure 124/74 mm Hg in both arms, the respiratory rate 16 breaths per minute, and the oxygen saturation 98% while the patient was breathing ambient air. The height was 170 cm, the weight 81.2 kg, and the body-mass index (the weight in kilograms divided by the square of the height in meters) 28.1. He was anxious and in mild discomfort. In the left supraclavicular fossa, there was a nontender, nonerythematous, nonmobile mass, measuring 6 cm by 4 cm, without overlying skin changes or a thrill or bruit. The deltopectoral incision was well healed. The jugular venous pulse on the right side was 5 cm of water with a normal contour, and both carotid pulses were 2+ without bruits. There was a systolic murmur (grade 1/6) at the left upper sternal border. Radial and ulnar pulses, strength, fine-motor coordination, and sensation to light touch and pinprick were symmetric in the left and right arms. The remainder of the examination was normal.



Biopsy Specimen of the Neck Mass. Hematoxylin and eosin staining was performed on sections of the biopsy specimen.

Panel A shows a fragment of mature hyaline cartilage (arrows) embedded in smooth muscle (asterisks). Panel B shows a fragment of bone (arrow) with underlying mesenchymal-type tissue (asterisk) overlying a fragment of mature hyaline cartilage (C). Panel C shows connective tissue with monotonous spindle cells arranged in a fascicular pattern (with one fascicle encircled), a finding consistent with smooth-muscle differentiation. Panel D shows a columnar epithelial-cell layer with scant apical cilia (arrows), which is consistent with respiratory epithelium, overlying connective tissue with an inflammatory infiltrate. Immunohistochemical staining for desmin (Panel E) shows strong, diffuse staining (in brown) in regions corresponding to smooth-muscle differentiation. Immunohistochemical staining for pan-cytokeratin (Panel F) shows strong, diffuse staining (in brown) of columnar cells in regions corresponding to epithelial differentiation.

The patient was readmitted for excision of the mass. A gross photograph of the excision specimen showed a tannish-white, ovoid mass with heterogeneous texture and regions of necrosis with hemorrhage. On microscopic examination, the mass contained a mixture of mature hyaline cartilage, bone, ciliated respiratory epithelium, and intestinal-type epithelium. In addition to bland mature elements, nodules of increased cellularity with large, confluent regions of necrosis were present. Cells in these nodular areas had a nested and corded growth pattern with comedonecrosis, cytologic atypia (nuclear enlargement, irregularity, and crowding), and apoptosis, findings that were suggestive of a malignant immature teratomatous epithelium. Immunohistochemical staining showed tumor cells that were strongly and diffusely positive for alpha-fetoprotein and negative for CD30, glypican-3, human chorionic gonadotropin, thyroid transcription factor 1, and CD117. Overall, the morphologic and immunohistochemical features were most compatible with metastatic postpubertal immature teratoma, which probably represented late metastatic disease from the patient's previously diagnosed mixed germ-cell tumor.

Metastatic postpubertal immature teratoma.



Excision Specimen of the Neck Mass. A gross photograph of the cut surface of the excision specimen (Panel A) shows a tannish-white, ovoid mass with multiple regions of necrosis (arrows) and interspersed hemorrhage. Hematoxylin and eosin staining was performed on sections of the excision specimen. Panel B shows mature hyaline cartilage (C), smooth muscle (asterisk), and columnar epithelium (arrow). Panel C shows columnar epithelial cells with apical cilia (arrows) and subnuclear vacuolization (arrowheads), with underlying smooth muscle (asterisk). Panel D shows nodules of highly cellular epithelium (arrows) adjacent to large, confluent regions of tumor necrosis (asterisks). At moderate magnification (Panel E), cords and nests of immature epithelium show multifocal regions of comedonecrosis (asterisks); immunohistochemical staining for alpha-fetoprotein (inset) shows strong, diffuse staining (in brown) of epithelial cells. At high magnification (Panel F), epithelial cells show enlarged, irregular, crowded nuclei with numerous mitoses (arrows) and apoptotic figures (arrowhead).

Endotheline sind Peptidhormone in Wirbeltieren, die hauptsächlich vom Endothel von Blutgefäßen produziert werden. Endotheline sind die stärksten bekannten vasokonstriktorischen Stoffe, sie wirken aber auch im Zentralnervensystem. Als blutgefäßverändernde (vasoaktive) Substanz ist es ein Bestandteil des körpereigenen Systems zur Regulierung des Blutdruckes und hochwirksamer Vasokonstriktor. Seine gefäßverengende und damit blutdrucksteigernde Wirkung ist einhundertmal mal so hoch wie die des Noradrenalins. Es wurde zunächst angenommen, dass es nur im Endothel, einer die Innenwand der Blutgefäße des gesamten Körpers auskleidenden Zellschicht, gebildet werde. Tatsächlich sind aber viele Zellen zur Bildung und Freisetzung von Endothelin in der Lage.
Insbesondere bei Erkrankungen der Herzkranzgefäße, Herzinsuffizienz und Arteriosklerose wird häufig ein erhöhter Endothelinspiegel beobachtet. Er beeinträchtigt auch die Kontraktionsfähigkeit des Herzens, den Herzrhythmus sowie die Durchblutung der Nieren. Seit einiger Zeit wird auch die Bedeutung von Endothelin bei verschiedenen Krebsarten, vor allem Prostata- und Brustkrebs, diskutiert. Die Wirkung von Endothelin kann mit Hilfe sogenannter Endothelinrezeptorantagonisten, im einfachsten Fall durch Blockade der Endothelinrezeptoren, gehemmt werden. Diese Antagonisten (z. B. Ambrisentan, Atrasentan, Bosentan, Clazosentan, Macitentan, Sitaxentan und Tezosentan) werden derzeit insbesondere als Orphan (Weisen)-Arzneimittel in der Therapie der pulmonalen arteriellen Hypertonie eingesetzt.





Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Summary

Background Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes.

Methods We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR) 25–75 mL/min per 1·73 m² of body surface area, and a urine albumin-to-creatinine ratio (UACR) of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders) were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days) or end-stage kidney disease (eGFR <15 mL/min per 1·73 m² sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure) in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532.

Findings Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325) or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%) of 1325 patients in the atrasentan group and 105 (7·9%) of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR] 0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%) of 1325 patients in the atrasentan group and 34 (2·6%) of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%) patients in the atrasentan group and 52 (3·9%) in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65).

Interpretation Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease.



Die Nicht-Reagierer

Die Reagierer

Nur die Reagierer



	Atrasentan (n=1325)	Placebo (n=1323)
Characteristics		
Age, years	64·9 (8·6)	64·7 (8·7)
Sex		
Women	331 (25·0%)	352 (26·6%)
Men	994 (75·0%)	971 (73·3%)
Race		
White	753 (56·8%)	744 (56·2%)
Black	73 (5·5%)	76 (5·7%)
Asian	446 (33·7%)	455 (34·4%)
Other	53 (4·0%)	48 (3·6%)
Weight, kg	84·6 (19·9)	84·6 (18·8)
Body-mass index, kg/m²	30·3 (5·8)	30·4 (5·5)
Duration of diabetes, years	16·8 (9·0)	16·7 (9·1)
Current smoker	205 (15·5%)	178 (13·5%)
Retinopathy	459 (34·6%)	453 (34·2%)
Blood pressure		
Systolic, mm Hg	136·5 (15·2)	136·2 (14·8)
Diastolic, mm Hg	75·0 (9·9)	74·8 (10·0)
Serum creatinine, µmol/L	147·5 (43·2)	147·4 (40·9)
Estimated glomerular filtration rate, mL/min per 1·73 m²	44·0 (13·7)	43·7 (13·7)
Cholesterol, mmol/L		
Total	4·6 (1·2)	4·6 (1·2)
Low-density lipoprotein	2·7 (1·0)	2·7 (1·0)
High-density lipoprotein	1·1 (0·4)	1·2 (0·4)
Glycated haemoglobin, %	7·8% (1·5)	7·8% (1·5)
Serum albumin, g/L	39·4 (3·5)	39·3 (3·4)
Haemoglobin, g/L	129·9 (16·9)	128·8 (16·9)
Brain natriuretic peptide, pg/mL	48·0 (26·0–87·0)	49·0 (25·6–89·0)
Serum potassium, mmol/L	4·5 (0·6)	4·5 (0·6)
Urinary albumin-to-creatinine ratio, mg/g	797 (462–1480)	805 (444–1451)
Previous medication		
Angiotensin-converting enzyme inhibitor	474 (35·8%)	487 (36·8%)
Angiotensin receptor blocker	861 (65·0%)	850 (64·2%)
β blocker	556 (42·0%)	541 (40·9%)
Calcium channel blocker	800 (60·4%)	775 (58·6%)
Diuretic		
Loop	595 (44·9%)	599 (45·3%)
Thiazide	409 (30·9%)	409 (30·9%)
Other*	127 (9·6%)	150 (11·3%)
Statin	965 (72·8%)	994 (75·1%)
Glucose-lowering therapies		
Insulin	838 (63·2%)	820 (62·0%)
Metformin	508 (38·3%)	534 (40·4%)
Sulphonylurea derivatives	374 (28·2%)	381 (28·8%)
Dipeptidyl peptidase 4 inhibitor	250 (18·9%)	295 (22·3%)
Glucagon-like peptide-1 receptor agonist	52 (3·9%)	56 (4·2%)
Sodium-glucose cotransporter 2 inhibitor	12 (0·9%)	24 (1·8%)
Antithrombotic drug†	753 (56·8%)	776 (58·7%)

Data are n (%), mean (SD), or median (IQR). *Chlorthalidone, indapamide, mefruside, metolazone, tripamide, and xipamide. †Anticoagulants and antiplatelets.

Table 1: **Baseline characteristics at start of the enrichment period**



Figure 2: UACR, systolic blood pressure, BNP, and bodyweight during the study

	Atrasentan (n=1325)		Placebo (n=1323)		Hazard ratio (95% CI)	p value*
	Number	Annual rate	Number	Annual rate		
Primary outcome						
Composite renal outcome	79 (6·0%)	2·8%	105 (7·9%)	3·7%	0·65 (0·49–0·88)	0·0047
Doubling of serum creatinine	56 (4·2%)	2·0%	78 (5·9%)	2·7%	0·61 (0·43–0·87)	0·0055
End-stage kidney disease	67 (5·1%)	2·4%	81 (6·1%)	2·9%	0·73 (0·53–1·01)	0·060
Secondary outcomes†						
50% eGFR reduction	84 (6·3%)	3·0%	99 (7·5%)	3·5%	0·73 (0·55–0·98)	0·038
Cardiorenal composite endpoint‡	147 (11·1%)	5·2%	172 (13·0%)	6·1%	0·80 (0·64–0·999)	0·049
Cardiovascular death	31 (2·3%)	1·1%	28 (2·1%)	1·0%	1·10 (0·66–1·83)	0·720
Non-fatal myocardial infarction	36 (2·7%)	1·3%	33 (2·5%)	1·2%	1·11 (0·69–1·78)	0·675
Non-fatal stroke	8 (0·6%)	0·3%	27 (2·0%)	1·0%	0·29 (0·13–0·64)	0·0021
Primary outcome in all randomly assigned patients§	152 (8·3%)	3·8%	192 (10·5%)	4·8%	0·72 (0·58–0·89)	0·0023
Cardiovascular composite endpoint¶	72 (5·4%)	2·5%	81 (6·1%)	2·9%	0·88 (0·64–1·22)	0·448
Other outcome						
Hospital admission for heart failure	47 (3·5%)	1·7%	34 (2·6%)	1·2%	1·33 (0·85–2·07)	0·208

Data are n (%) unless otherwise specified. eGFR=estimated glomerular filtration rate. Annual rates are numbers of events over total person-years of follow-up. *Cox model for the primary and secondary efficacy outcomes; the log-rank p value was 0·029 for the primary outcome; 0·163 for the time to a 50% eGFR reduction; 0·011 for primary outcome in the total population; and 0·446 for cardiovascular composite endpoint. †Secondary outcomes are ranked according to prespecified hierarchy. ‡Comprises doubling of serum creatinine, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. §Primary renal outcome in combined responders and non-responders (n=1834 atrasentan and n=1834 placebo). ¶Comprises cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke.

Table 2: **Effects of atrasentan on renal and cardiovascular outcomes**



Figure 3: Effects of atrasentan on the primary composite renal outcome and its components in responders



Figure 4: Effects of atrasentan on the primary composite renal outcome in non-responders and all responders and non-responders combined

	Atrasentan (n=1321)	Placebo (n=1320)	p value*
Any serious adverse event	479 (36·3%)	430 (32·6%)	0·049
Adverse events leading to discontinuation	137 (10·4%)	122 (9·2%)	0·360
Deaths	58 (4·4%)	52 (3·9%)	0·630
Treatment-emergent adverse events of interest			
Hypervolaemia or fluid retention	483 (36·6%)	426 (32·3%)	0·022
Cardiac failure†	72 (5·5%)	51 (3·9%)	0·064
Anaemia	244 (18·5%)	136 (10·3%)	<0·0001
Vasodilation	126 (9·5%)	118 (8·9%)	0·638
Cardiac toxicity	147 (11·1%)	130 (9·8%)	0·310
Serious adverse events (>1% in either group)			
Acute kidney injury	32 (2·4%)	28 (2·1%)	0·696
Pneumonia	32 (2·4%)	22 (1·7%)	0·216
Congestive cardiac failure	23 (1·7%)	15 (1·1%)	0·252
Acute myocardial infarction	21 (1·6%)	21 (1·6%)	1·0
Coronary artery disease	18 (1·4%)	17 (1·3%)	1·0
Anaemia	16 (1·2%)	10 (0·8%)	0·325
Hypoglycaemia	14 (1·1%)	8 (0·6%)	0·284
Urinary tract infection	16 (1·2%)	7 (0·5%)	0·092
Cardiac failure	13 (1·0%)	8 (0·6%)	0·381
Cataract	16 (1·2%)	8 (0·6%)	0·150
Hyperkalaemia	13 (1·0%)	13 (1·0%)	1·0

Data are n (%). *Fisher's exact test. †Cardiac failure events included all investigator-reported treatment-emergent adverse events.

Table 3: **Adverse events during double-blind treatment period**

Research in context

Evidence before this study

We searched PubMed for all English-language publications published between Jan 1, 1990, and Feb 15, 2018, with the search terms "endothelin-1", "endothelin receptor antagonist", "albuminuria", "kidney disease", "diabetes", "nephropathy", and "randomised controlled trial". Since the introduction of blood pressure control and renin–angiotensin–aldosterone blockade with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, no additional therapy that lowers albuminuria has been shown to improve long-term renal outcomes. Endothelin receptor antagonists reduce albuminuria in experimental models of diabetes and in clinical studies of patients with chronic kidney disease with or without diabetes. A large randomised controlled trial in patients with type 2 diabetes and chronic kidney disease using the fairly unselective endothelin receptor antagonist avosentan was terminated early because of an increased frequency of heart failure with avosentan. Atrasentan is a more selective endothelin receptor antagonist which, in short-term studies, reduced albuminuria with minimal sodium retention in patients with type 2 diabetes and chronic kidney disease. These preliminary findings justify conducting a phase 3 clinical trial to establish whether atrasentan can delay progression to end-stage kidney disease.

Added value of this study

We describe the results of a randomised, double-blind, placebo-controlled, phase 3 trial designed to study the efficacy and safety of the endothelin receptor antagonist atrasentan as an adjunct to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy for reducing the frequency of renal disease progression in patients with type 2 diabetes and chronic kidney disease. To enhance the likelihood of detecting a treatment benefit while minimising the risk of heart failure, the trial used an enrichment design. Atrasentan responders were selected on the basis of the degree of albuminuria reduction during a 6-week atrasentan treatment period, while excluding patients who had fluid retention during this period to minimise the risk of heart failure. To our knowledge, this is the first clinical trial in patients with type 2 diabetes to use an enrichment-responder design. During a median follow-up of 2·2 years, atrasentan reduced the rate of the primary renal endpoint compared with placebo (n=79 [6·0%] vs 105 [7·9%]; hazard ratio [HR] 0·65; 95% CI 0·49–0·88; p=0·0047). Hospital admission for heart failure occurred in 47 (3·5%) patients in the atrasentan group and 34 (2·6%) patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208).

Implications of all the available evidence

Patients identified as showing substantial albuminuria reduction and minimal signs of sodium retention during short-term treatment with low-dose atrasentan had a significantly reduced risk of a renal event during long-term treatment with atrasentan compared with placebo. These data support a role for atrasentan in modifying renal risk in selected patients with type 2 diabetes and chronic kidney disease.

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

Summary

Background Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy of the docetaxel-based triplet FLOT (fluorouracil plus leucovorin, oxaliplatin and docetaxel) as a perioperative therapy for patients with locally advanced, resectable tumours.

Methods In this controlled, open-label, phase 2/3 trial, we randomly assigned 716 patients with histologically-confirmed advanced clinical stage cT2 or higher or nodal positive stage (cN+), or both, resectable tumours, with no evidence of distant metastases, via central interactive web-based-response system, to receive either three pre-operative and three postoperative 3-week cycles of 50 mg/m² epirubicin and 60 mg/m² cisplatin on day 1 plus either 200 mg/m² fluorouracil as continuous intravenous infusion or 1250 mg/m² capecitabine orally on days 1 to 21 (ECF/ECX; control group) or four preoperative and four postoperative 2-week cycles of 50 mg/m² docetaxel, 85 mg/m² oxaliplatin, 200 mg/m² leucovorin and 2600 mg/m² fluorouracil as 24-h infusion on day 1 (FLOT; experimental group). The primary outcome of the trial was overall survival (superiority) analysed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01216644.

Findings Between Aug 8, 2010, and Feb 10, 2015, 716 patients were randomly assigned to treatment in 38 German hospitals or with practice-based oncologists. 360 patients were assigned to ECF/ECX and 356 patients to FLOT. Overall survival was increased in the FLOT group compared with the ECF/ECX group (hazard ratio [HR] 0·77; 95% confidence interval [CI; 0.63 to 0·94]; median overall survival, 50 months [38·33 to not reached] *vs* 35 months [27·35 to 46·26]). The number of patients with related serious adverse events (including those occurring during hospital stay for surgery) was similar in the two groups (96 [27%] in the ECF/ECX group *vs* 97 [27%] in the FLOT group), as was the number of toxic deaths (two [<1%] in both groups). Hospitalisation for toxicity occurred in 94 patients (26%) in the ECF/ECX group and 89 patients (25%) in the FLOT group.

Interpretation In locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma, perioperative FLOT improved overall survival compared with perioperative ECF/ECX.

	ECF/ECX (n=360)	FLOT (n=356)
Age (years)		
Median	62 (52–69)	62 (54–69)
<60	160 (44%)	155 (44%)
60–69	113 (31%)	116 (33%)
≥70	87 (24%)	85 (24%)
Sex		
Male	265 (74%)	268 (75%)
Female	95 (26%)	88 (25%)
ECOG		
0	254 (71%)	246 (69%)
1	103 (29%)	109 (31%)
2	3 (1%)	1 (<1%)
Location		
GEJ Siewert type 1*	85 (24%)	80 (23%)
GEJ Siewert type 2 or 3	115 (32%)	118 (33%)
Stomach	160 (44%)	158 (44%)
cT-stage†		
T1	2 (1%%)	3 (1%)
T2	59 (16%)	49 (14%)
T3	253 (70%)	267 (75%)
T4	33 (9%)	28 (8%)
unclear	13 (4%)	9 (3%)
cN-stage†		
N–	70 (19%)	77 (22%)
N+	290 (81%)	279 (78%)
Barrett's carcinoma‡		
Yes	54 (15%)	53 (15%)
No	297 (83)	301 (85%)
Unclear or unknown	4 (1%)	2 (1%)
Missing	5 (1%)	0 (0)
Lauren's type		
Diffuse	96 (27%)	95 (27%)
Intestinal or mixed	163 (45%)	159 (45%)
Not evaluable according to Lauren	72 (20%)	70 (20%)
Missing	29 (8%)	32 (9%)

(Table 1 continues in next column)

(Continued from previous column)

	ECF/ECX (n=360)	FLOT (n=356)
Signet cells§		
Yes	101 (28%)	100 (28%)
No	234 (65%)	245 (69%)
Missing	25 (7%)	11 (3%)
Grading according to WHO¶		
G1	21 (6%)	12 (3%)
G2	131 (36%)	123 (35%)
G2–3	10 (3%)	12 (3%)
G3	177 (49%)	177 (50%)
Missing	21 (6%)	32 (9%)

Data are median (IQR) or n (%). Percentages might not add up to 100 because of rounding. ECF=epirubicin, cisplatin, and fluorouracil. ECX=epirubicin, cisplatin, and capecitabine. FLOT=fluorouracil, leucovorin, oxaliplatin, and docetaxel. ECOG=Eastern Cooperative Oncology Group. GEJ=gastro-oesophageal junction. cN+=nodal positive. cN–=nodal negative. *Adenocarcinomas of the gastro-oesophageal junction were classified according to the Siewert classification as tumours having their centre 5 cm proximal or distal of the anatomical cardia. Siewert type 1 tumours are described as adenocarcinoma of the distal oesophagus, which usually arises from an area with specialised intestinal metaplasia of the oesophagus (ie, Barrett's oesophagus) and which might infiltrate the oesophagogastric junction from above.[19] Note, Siewert type 1 tumours might not involve the junction and might have been classified as oesophageal adenocarcinomas in other studies. †Clinical tumour stage and clinical nodal (cN) stage were assessed by endoscopic ultrasound and CT or MRI and classified according to the seventh version of the International Union against Cancer tumour–node–metastasis classification. ‡Barrett's carcinoma was defined as the presence of Barrett's mucosa in tumours of the gastro-oesophageal junction as assessed by either baseline endoscopy or pathological examination. Stomach tumours were automatically regarded non-Barrett. §Defined as the presence of any signet cells. ¶WHO performance status scores are on a scale of 0 to 5, with lower numbers indicating better performance status; 0 indicates fully active and 1 unable to carry out heavy physical work.

Table 1: **Baseline characteristics of the intention-to-treat population according to treatment group**

	ECF/ECX (n=360)	FLOT (n=356)
Proceeded to surgery	341 (95%)	345 (97%)
Received tumour surgery	314 (87%)	336 (94%)
Achieved margin-free (R0) resection	279 (78%)	301 (85%)
Type of surgery		
Transthoracic oesophagectomy	98 (27%)	109 (31%)
Gastrectomy with or without transhiatal oesophagectomy	200 (56%)	208 (58%)
Multivisceral resection	10 (3%)	15 (4%)
Other tumour surgery	6 (2%)	4 (1%)
Palliative (non-curative) resection	6 (2%)	0 (0)
Non-resectional surgery	21 (6%)	9 (3%)
No surgery	19 (5%)	11 (3%)
Median number of lymph nodes removed*	25·0 (19–33)	24·0 (18–32)
Type of lymphadenectomy		
2-Field	106 (29%)	113 (32%)
D2	192 (53%)	204 (57%)
3-Field	2 (1%)	1 (<1%)
D3	5 (1%)	10 (3%)
D1	7 (2%)	5 (1%)
Missing	7 (2%)	3 (1%)
Not applicable or D0†	41 (11%)	20 (6%)
Tumour stage (ypT)		
≤T1	53 (15%)	88 (25%)
T2	44 (12%)	44 (12%)
T3	175 (49%)	165 (46%)
T4	47 (13%)	37 (10%)
Not applicable†	41 (11%)	22 (6%)
Nodal status (ypN)		
N0	146 (41%)	174 (49%)
N1	44 (12%)	55 (16%)
N2	54 (15%)	47 (13%)
N3	73 (20%)	57 (16%)
Not applicable†	43 (12%)	23 (7%)

Data are median (IQR) or n (%). Percentages may not add up to 100 because of rounding. ECF=epirubicin, cisplatin, and fluorouracil. ECX=epirubicin, cisplatin, and capecitabine. FLOT=fluorouracil plus leucovorin, oxaliplatin, and docetaxel. ypT=postoperative T-stage following preoperative chemotherapy. ypN=postoperative N-stage following preoperative chemotherapy. *Numbers were calculated in the group of patients who had tumour surgery. †Includes patients who could not be staged due to no operation, palliative surgery, or others.

Table 2: **Surgical and pathology results in the intention-to-treat population according to treatment group**



Figure 2: **Kaplan–Meier estimates of overall survival (A) and disease-free survival (B)**

	ECF/ECX (n=354)		FLOT (n=354)		Difference in grade 3 or 4 events (p value)
	Grade 1 or 2	Grade 3 or 4	Grade 1 or 2	Grade 3 or 4	
Diarrhoea	103 (29%)	13 (4%)	182 (52%)	34 (10%)	0·0016
Vomiting	102 (29%)	27 (8%)	113 (32%)	7 (2%)	<0·001
Nausea	215 (61%)	55 (16%)	211 (60%)	26 (7%)	<0·001
Constipation	86 (24%)	1 (<1%)	75 (21%)	2 (1%)	0·56
Stomatitis or mucositis	107 (30%)	10 (3%)	99 (28%)	5 (1%)	0·19
Leukopenia	175 (49%)	75 (21%)	180 (51%)	94 (27%)	0·098
Neutropenia	93 (26%)	139 (39%)	84 (24%)	181 (51%)	0·0017
Anaemia	282 (80%)	20 (6%)	283 (80%)	9 (3%)	0·036
Thrombocytopenia	123 (35%)	11 (3%)	137 (39%)	7 (2%)	0·34
Serum AST	41 (12%)	1 (<1%)	116 (33%)	3 (1%)	0·31
Serum ALT	55 (16%)	1 (<1%)	127 (36%)	8 (2%)	0·019
Fever	29 (8%)	2 (1%)	77 (22%)	4 (1%)	0·41
Peripheral neuropathy	120 (34%)	7 (2%)	228 (64%)	24 (7%)	0·0018
Pain	171 (48%)	14 (4%)	166 (47%)	21 (6%)	0·23
Alopecia*	147 (42%)	74 (21%)	122 (35%)	98 (28%)	NA
Renal	99 (28%)	1 (<1%)	38 (11%)	0 (0)	0·32
Infections	62 (18%)	30 (9%)	61 (17%)	63 (18%)	<0·001
Thromboembolic	31 (9%)	21 (6%)	13 (4%)	9 (3%)	0·025
Toxic death†	..	2 (<1%)	..	2 (<1%)	1·0

Except for toxic deaths, adverse events are displayed when they were observed in 20% or more patients at grade 1 or 2 or 5% or more patients at grade 3 or 4. ECF=epirubicin, cisplatin, and fluorouracil. ECX=epirubicin, cisplatin, and capecitabine. FLOT=fluorouracil plus leucovorin, oxaliplatin, and docetaxel. AST=aspartate aminotransferase. ALT=alanine-aminotransferase. NA=not applicable. *The highest grade of alopecia was grade 2, which is listed in the grade 3 or 4 column. †Toxic death was defined as a chemotherapy-related toxicity resulting in death.

***Table* 3: Potentially chemotherapy-associated adverse events (whether related or not) assessed in the safety population according to treatment group**



Research in context

Evidence before this study

For this manuscript we searched PubMed and the abstracts of major oncology congresses (American Society of Clinical Oncology [ASCO] and ASCO Gastrointestinal Symposium, and European Society for Medical Oncology) from Jan 1 to May 25, 2018. For the PubMed search, we used full-text search terms for "gastric cancer", "oesophageal cancer" or "gastro-oesophageal junction cancer" in conjunction with "neoadjuvant treatment" or "perioperative treatment" as well as "resectable" or "operable stage" or "operable patients". We limited our discussion to trials and reports that we found relevant to the setting of our trial as well as our population, and results.
The prognosis of patients with gastric cancer was poor in the more advanced tumours. Perioperative chemotherapy for gastric and gastro-oesophageal junction adenocarcinoma was established and shown to improve survival in two landmark clinical trials: the MAGIC trial using three 3-week cycles of ECF (epirubicin and cisplatin plus fluorouracil) followed by surgery followed by three additional ECF cycles showing significant improvement in 5-year overall survival (36% *vs* 23%) and the French FNCLCC/FFCD 9703·3 study, in which patients received 2–3 cycles of cisplatin with flourouracil before and after surgery or surgery alone, resulting in a significant and similar improvement of 5-year overall survival (38% *vs* 24%). However, despite these advances, the outcome for patients with advanced gastric or gastric and gastro-oesophageal junction adenocarcinoma remained unsatisfactory. At that time, docetaxel had proven efficacy in metastatic gastric cancer, both in first-line and second-line settings. Our group previously demonstrated the activity and safety of the docetaxel-based triple combination FLOT, consisting of fluorouracil, leucovorin, oxaliplatin, and docetaxel, administered every 2 weeks in the treatment of patients with metastatic gastric cancer and found FLOT induced pathological complete regression of up to 17% in phase 2 and retrospective studies.

Added value of this study

To our knowledge, this is the first trial to show significant improvement over the available standard of care ECF in the treatment of patients with locally advanced, potentially resectable gastric and gastro-oesophageal junction adenocarcinoma. The study showed that perioperative FLOT significantly improved overall survival as compared with perioperative ECF or ECX (epirubicin and cisplatin plus either fluorouracil or capecitabine.

Implications of all the available evidence

The study expands the available options for the treatment of locally advanced, resectable gastric and gastro-oesophageal adenocarcinoma.

Health effects of dietary risks in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

Summary

Background Suboptimal diet is an important preventable risk factor for non-communicable diseases (NCDs); however, its impact on the burden of NCDs has not been systematically evaluated. This study aimed to evaluate the consumption of major foods and nutrients across 195 countries and to quantify the impact of their suboptimal intake on NCD mortality and morbidity.

Methods By use of a comparative risk assessment approach, we estimated the proportion of disease-specific burden attributable to each dietary risk factor (also referred to as population attributable fraction) among adults aged 25 years or older. The main inputs to this analysis included the intake of each dietary factor, the effect size of the dietary factor on disease endpoint, and the level of intake associated with the lowest risk of mortality. Then, by use of disease-specific population attributable fractions, mortality, and disability-adjusted life-years (DALYs), we calculated the number of deaths and DALYs attributable to diet for each disease outcome.

Findings In 2017, 11 million (95% uncertainty interval [UI] 10–12) deaths and 255 million (234–274) DALYs were attributable to dietary risk factors. High intake of sodium (3 million [1–5] deaths and 70 million [34–118] DALYs), low intake of whole grains (3 million [2–4] deaths and 82 million [59–109] DALYs), and low intake of fruits (2 million [1–4] deaths and 65 million [41–92] DALYs) were the leading dietary risk factors for deaths and DALYs globally and in many countries. Dietary data were from mixed sources and were not available for all countries, increasing the statistical uncertainty of our estimates.

Interpretation This study provides a comprehensive picture of the potential impact of suboptimal diet on NCD mortality and morbidity, highlighting the need for improving diet across nations. Our findings will inform implementation of evidence-based dietary interventions and provide a platform for evaluation of their impact on human health annually.

	Exposure definition	Optimal level of intake (optimal range of intake)	Data representativeness index (%)
Diet low in fruits	Mean daily consumption of fruits (fresh, frozen, cooked, canned, or dried fruits, excluding fruit juices and salted or pickled fruits)	250 g (200–300) per day	94·9
Diet low in vegetables	Mean daily consumption of vegetables (fresh, frozen, cooked, canned, or dried vegetables, excluding legumes and salted or pickled vegetables, juices, nuts, seeds, and starchy vegetables such as potatoes or corn)	360 g (290–430) per day	94·9
Diet low in legumes	Mean daily consumption of legumes (fresh, frozen, cooked, canned, or dried legumes)	60 g (50–70) per day	94·9
Diet low in whole grains	Mean daily consumption of whole grains (bran, germ, and endosperm in their natural proportion) from breakfast cereals, bread, rice, pasta, biscuits, muffins, tortillas, pancakes, and other sources	125 g (100–150) per day	94·9
Diet low in nuts and seeds	Mean daily consumption of nut and seed foods	21 g (16–25) per day	94·9
Diet low in milk	Mean daily consumption of milk including non-fat, low-fat, and full-fat milk, excluding soy milk and other plant derivatives	435 g (350–520) per day	94·9
Diet high in red meat	Mean daily consumption of red meat (beef, pork, lamb, and goat, but excluding poultry, fish, eggs, and all processed meats)	23 g (18–27) per day	94·9
Diet high in processed meat	Mean daily consumption of meat preserved by smoking, curing, salting, or addition of chemical preservatives	2 g (0–4) per day	36·9
Diet high in sugar-sweetened beverages	Mean daily consumption of beverages with ≥50 kcal per 226·8 serving, including carbonated beverages, sodas, energy drinks, fruit drinks, but excluding 100% fruit and vegetable juices	3 g (0–5) per day	36·9
Diet low in fibre	Mean daily intake of fibre from all sources including fruits, vegetables, grains, legumes, and pulses	24 g (19–28) per day	94·9
Diet low in calcium	Mean daily intake of calcium from all sources, including milk, yogurt, and cheese	1·25 g (1·00–1·50) per day	94·9
Diet low in seafood omega-3 fatty acids	Mean daily intake of eicosapentaenoic acid and docosahexaenoic acid	250 mg (200–300) per day	94·9
Diet low in polyunsaturated fatty acids	Mean daily intake of omega-6 fatty acids from all sources, mainly liquid vegetable oils, including soybean oil, corn oil, and safflower oil	11% (9–13) of total daily energy	94·9
Diet high in trans fatty acids	Mean daily intake of trans fat from all sources, mainly partially hydrogenated vegetable oils and ruminant products	0·5% (0·0–1·0) of total daily energy	36·9
Diet high in sodium	24 h urinary sodium measured in g per day	3 g (1–5) per day*	26·2

*To reflect the uncertainty in existing evidence on optimal level of intake for sodium, 1–5 g per day was considered as the uncertainty range for the optimal level of sodium where less than 2·3 g per day is the intake level of sodium associated with the lowest level of blood pressure in randomised controlled trials and 4–5 g per day is the level of sodium intake associated with the lowest risk of cardiovascular disease in observational studies.

Table: **Dietary risk factor exposure definitions, optimal level, and data representativeness index, 1990–2017**


Global
Southeast Asia, east Asia, and Oceania
Central Europe, eastern Europe, and central Asia
High income
Latin America and the Caribbean
North Africa and the Middle East
South Asia
Sub-Saharan Africa
Global intake in 2017
Optimal level of intake (according to the midpoint of the optimal range of intake)
Global
East Asia
Southeast Asia
Oceania
Central Asia
Central Europe
Eastern Europe
High-income Asia Pacific
Australasia
Western Europe
Southern Latin America
High-income North America
Caribbean
Andean Latin America
Central Latin America
Tropical Latin America
North Africa and Middle East
South Asia
Central sub-Saharan Africa
Eastern sub-Saharan Africa
Southern sub-Saharan Africa
Western sub-Saharan Africa
Fruits (g per day)
Vegetables (g per day)
Legumes (g per day)
Whole grains (g per day)
Nuts and seeds (g per day)
Milk (g per day)
Calcium (g per day)
Fibre (g per day)
Omega-3 fatty acids (g per day)
PUFA (percentage of total dietary energy)
Red meat (g per day)
Processed meat (g per day)
Sugar-sweetened beverages (g per day)
Trans fats (percentage of total dietary energy)
Sodium (g per day)



Figure 2: Age-standardised mortality rate per 100 000 population (A) and DALY rate per 100 000 population (B) attributable to diet in 2017


A
Mortality rate attributable to diet
Number of deaths at the global level attributable to diet
Diet high in sodium
Diet low in whole grains
Diet low in fruits
Diet low in nuts and seeds
Diet low in vegetables
Diet low in seafood omega-3 fatty acids
Diet low in fibre
Diet low in polyunsaturated fatty acids
Diet low in legumes
Diet high in trans fats
Diet low in calcium
Diet high in sugar-sweetened beverages
Diet high in processed meat
Diet low in milk
Diet high in red meat
Location
High-middle SDI
High SDI
Middle SDI
Low SDI
Low-middle SDI
Cause
Cardiovascular diseases
Type 2 diabetes
Neoplasms
Other causes
120 100 80 60 40 20 0
Deaths rate (per 100 000 population)
0 1000 2000 3000
Number of deaths (in thousands)
B
DALY rate attributable to diet
Number of DALYs at the global level attributable to diet
Diet low in whole grains
Diet high in sodium
Diet low in fruits
Diet low in nuts and seeds
Diet low in vegetables
Diet low in seafood omega-3 fatty acids
Diet low in fibre
Diet low in polyunsaturated fatty acids
Diet low in legumes
Diet high in trans fats
Diet high in sugar-sweetened beverages
Diet low in calcium
Diet high in processed meat
Diet low in milk
Diet high in red meat
Location
High-middle SDI
High SDI
Middle SDI
Low SDI
Low-middle SDI
Cause
Cardiovascular diseases
Type 2 diabetes
Neoplasms
Other causes
2500 2000 1500 1000 500 0
DALYs rate (per 100 000 population)
0 20 000 40 000 60 000 80 000
Number of DALYs (in thousands)

Figure 4: **Age-standardised proportions of deaths and DALYs attributable to individual dietary risks at the global and regional level in 2017**

Research in context

Evidence before this study

We systematically searched MEDLINE and the Global Health Data Exchange (GHDx) to identify studies providing nationally or subnationally representative estimates of consumption of 15 foods and nutrients. We included only studies reporting data collected between Jan 1, 1980, and Dec 31, 2016, in one of the 195 countries included in this analysis. Studies were excluded if done with non-random samples or among specific subpopulations. We estimated the potential health effects of each dietary risk by use of the Global Burden of Diseases, Injuries, and Risk Factors Study comparative risk assessment approach.

Added value of this study

This study provides a comprehensive picture of consumption of 15 dietary factors across nations and quantifies the potential impact of suboptimal intake of each diet component on chronic disease mortality and morbidity among 195 countries. Additionally, this study characterises the relationship between diet and development and evaluates the trends in the burden of disease attributable to diet from 1990 to 2017. High intake of sodium, low intake of whole grains, and low intake of fruits were the leading dietary risk factors for deaths and DALYs globally and in many countries.

Implications of all the available evidence

This study highlights the need for improving diet at the global, regional, and national level. The findings inform priorities for population-level interventions to improve diet.

Maternal and perinatal mortality and complications associated with caesarean section in low-income and middle-income countries: a systematic review and meta-analysis

Summary

Background Universal and timely access to a caesarean section is a key requirement for safe childbirth. We identified the burden of maternal and perinatal mortality and morbidity, and the risk factors following caesarean sections in low-income and middle-income countries (LMICs).

Methods For this systematic review and meta-analysis, we searched electronic databases including MEDLINE and Embase (from Jan 1, 1990, to Nov 20, 2017), without language restrictions, for studies on maternal or perinatal outcomes following caesarean sections in LMICs. We excluded studies in high-income countries, those involving non-pregnant women, case reports, and studies published before 1990. Two reviewers undertook the study selection, quality assessment, and data extraction independently. The main outcome being assessed was prevalence of maternal mortality in women undergoing caesarean sections in LMICs. We used a random effects model to synthesise the rate data, and reported the association between risk factors and outcomes using odds ratios with 95% CIs. The study protocol has been registered with PROSPERO, number CRD42015029191.

Findings We included 196 studies from 67 LMICs. The risk of maternal death in women who had a caesarean section (116 studies, 2 933 457 caesarean sections) was 7·6 per 1000 procedures (95% CI 6·6–8·6, τ^2=0·81); the highest burden was in sub-Saharan Africa (10·9 per 1000; 9·5–12·5, τ^2=0·81). A quarter of all women who died in LMICs (72 studies, 27 651 deaths) had undergone a caesarean section (23·8%, 95% CI 21·0–26·7; τ^2=0·62).

Interpretation Maternal deaths and perinatal deaths following caesarean sections are disproportionately high in LMICs. The timing and urgency of caesarean section pose major risks.



Figure 1: **Study selection**

	Studies or cohorts	Maternal deaths (n)	Caesarean sections (N)	Risk (n/N per 1000; 95% CI)	τ^2	p value for interaction
Region*	..	..	..	..	..	0·011
Sub-Saharan Africa	87	5843	1891505	10·9 (9·5–12·5)	0·81	..
South Asia	13	266	77239	4·3 (2·0–7·3)	1·75	..
East Asia and Pacific	5	121	115866	0·9 (0·3–1·9)	0·49	..
Europe and central Asia	2	51	130596	0·3 (0·2–0·4)	0·00	..
Latin America and the Caribbean	3	379	534734	0·9 (0·4–1·4)	0·10	..
Middle East and north Africa	4	37	27662	3·2 (0·3–8·3)	4·54	..
Year of study	..	..	..	..	..	0·27
Before 2000	24	947	298976	9·7 (6·3–13·7)	1·31	..
2000 or later	92	6035	2634481	6·9 (5·9–7·9)	1·59	..
Study design	..	..	..	..	..	0·58
Prospective	49	1780	344042	8·0 (5·7–10·6)	1·43	..
Retrospective	67	5202	2589415	7·8 (6·7–8·9)	1·62	..
Income setting	..	..	..	..	..	0·012
Low	50	1904	138827	13·2 (10·1–16·7)	0·99	..
Lower-middle	23	474	129634	3·1 (1·8–4·6)	0·46	..
Upper-middle	41	4336	2509141	5·4 (4·5–6·4)	2·18	..
Quality of study	..	..	..	..	..	0·063
Low	28	1351	134999	10·0 (6·4–14·2)	1·34	..
High	88	5631	2798458	6·9 (6·0–7·8)	1·58	..
Type of hospital	..	..	..	..	..	0·014
District hospital	18	167	19393	8·7 (5·9–11·9)	0·39	..
Mixed†	29	5185	2484212	5·1 (3·9–6·4)	2·47	..
Private hospital	1	3	1120	2·7 (0·9–7·8)	..	..
Tertiary or teaching hospital	66	1359	272877	10·3 (7·5–13·4)	1·27	..
Overall	116	6982	2933457	7·6 (6·6–8·6)	0·81	..

*Represents cohorts instead of studies according to the collapsed WHO multi-country and global surveys. †Includes some district hospitals and some tertiary hospitals.

Table 1: **Risk of maternal death in women who have undergone caesarean sections in low-income and**



Figure 2: **Quality of studies evaluating caesarean section deaths as a proportion of all caesarean sections**



Figure 3: World map of maternal death risk following caesarean section in women from low-income and middle-income countries

	Studies or cohorts	Caesarean section deaths (n)	Total maternal deaths (N)	Prevalence (% per 100; 95% CI)	τ^2	p value for interaction
Region*	..	..	..	..	..	0·012
Sub-Saharan Africa	31	4330	17 219	22·0 (18·8–25·4)	0·67	..
East Asia and Pacific	11	610	3398	18·4 (15·9–21·1)	0·04	..
Middle East and north Africa	14	855	3177	34·5 (21·6–48·7)	1·11	..
South Asia	12	355	2364	20·7 (13·8–28·5)	0·35	..
Latin America and the Caribbean	1	202	459	44·0 (39·5–48·6)	-	..
Europe and central Asia	1	50	174	28·7 (22·5–35·9)	-	..
Year of study	..	..	..	..	..	0·87
Before 2000	28	1325	6162	23·5 (18·7–28·7)	0·49	..
2000 or later	44	5345	21 489	24·0 (20·6–27·7)	0·71	..
Study design	..	..	..	..	..	0·11
Prospective	11	570	1893	28·8 (22·0–36·1)	0·42	..
Retrospective	61	6100	25 758	22·9 (20·0–26·1)	0·64	..
Income setting	..	..	..	..	..	0·31
Low	13	696	2287	25·2 (16·2–35·4)	0·60	..
Lower-middle	34	1034	5975	21·0 (16·0–26·4)	0·71	..
Upper-middle	22	4660	18 474	25·9 (22·4–30·0)	0·47	..
Quality	..	..	..	..	..	0·48
Low	9	213	844	20·3 (11·4–31·0)	0·73	..
High	63	6457	26 807	24·2 (21·3–27·3)	0·61	..
Overall	72	6670	27 651	23·8 (21·0–26·7)	0·62	..

*Represents cohorts instead of studies according to the collapsed WHO multi-country and global surveys.

Table 2: **Caesarean section deaths as a proportion of all maternal deaths in low-income and middle-income countries**

	Studies or cohorts	Perinatal deaths (n)	Caesarean sections (N)	Prevalence (per 1000; 95% CI)	τ^2	p value for interaction
Region*	..	..	..	..	..	0·011
Sub-Saharan Africa	67	9804	105 089	100·4 (83·9–118·3)	1·14	..
South Asia	13	1816	48 031	56·9 (35·8–82·3)	1·21	..
East Asia and Pacific	8	882	8152	29·5 (0·0–113·9)	1·72	..
Europe and central Asia	1	7	3817	1·8 (0·9–3·8)	..	..
Latin America and the Caribbean	1	494	10 643	46·4 (42·6–50·6)	..	..
Middle East and north Africa	2	1459	3819	354·6 (339·5–369·8)	4·86	..
Year of study	..	..	..	..	..	0·059
Before 2000	23	6828	55 906	116·3 (75·5–164·5)	1·03	..
2000 or later	70	9636	191 469	74·7 (62·1–88·3)	1·74	..
Study design	..	..	..	..	..	0·093
Prospective	47	8116	167 910	70·9 (57·1–86·1)	1·64	..
Retrospective	46	8348	79 465	98·8 (71·4–130·0)	1·50	..
Income setting	..	..	..	..	..	0·012
Low	38	6024	59 233	111·8 (86·0–140·3)	1·23	..
Lower-middle	26	6599	93 186	66·0 (40·7–96·7)	1·47	..
Upper-middle	28	1839	27 132	71·7 (45·0–103·8)	1·97	..
Quality	..	..	..	..	..	0·53
Low	25	4152	46 121	90·6 (71·7–111·3)	0·89	..
High	68	12 312	201 254	82·7 (65·4–101·7)	1·85	..
Type of hospital	..	..	..	..	..	0·014
District hospital	16	929	12 816	75·0 (38·5–122·0)	1·34	..
Mixed†	18	5302	75 585	119·2 (86·7–156·1)	1·10	..
Private hospital	1	43	1120	38·4 (28·6–51·3)	..	..
Tertiary or teaching hospital	57	8188	90 030	79·7 (58·0–104·4)	1·82	..
Overall	93	16 464	247 375	84·7 (70·5–100·2)	1·61	..

*Represents cohorts instead of studies according to the collapsed WHO country and global surveys. †Includes some district hospitals and some tertiary hospitals.

***Table 3*: Perinatal deaths after caesarean sections in low-income and middle-income countries in a systematic review**



Figure 4: Risk factors for caesarean section-related mortality and morbidity

Research in context

Evidence before this study

Our search between Jan 1, 1990, and Nov 20, 2017, using MeSH headings, text words, and word variants for pregnancy, caesarean section, and low-income and middle-income countries identified only one meta-analysis to date on the risks of surgery in low-income and middle-income countries (LMICs), which provided estimates of maternal mortality following caesarean sections by use of modelled data with assumptions. Whether the risks varied according to the country's income status, numbers of caesarean sections, setting, study quality, and year were not assessed. Perinatal outcomes and risk of other complications after caesarean sections are not known. Risk factors for complications after surgery are also not known.

Added value of this study

We included five times the number of studies than in the previous review, and provided robust estimates of maternal and perinatal death risk following a caesarean section in LMICs. We identified the high-risk regions, income status, and care settings for maternal and perinatal mortality. Caesarean section deaths were reported alongside rates of procedure in individual countries. Emergency caesarean sections, particularly in the second stage, were major risk factors for complications. Most caesarean sections were done as a result of failure to progress, and post-partum haemorrhage was the main cause of maternal death.

Implications of all the available evidence

Caesarean sections are a disproportionate threat to the lives of women and babies in LMICs. The sub-Saharan region and low-income countries require targeted intervention. Countries with low rates of caesarean sections have high maternal deaths and need improved access. Evidence-based training in labour management with monitoring the indications is needed to reduce inappropriate caesarean sections. Multidisciplinary surgical training with resource provision, skills training in instrumental deliveries, and management of post-partum haemorrhage and neonatal resuscitation can help to reduce maternal and perinatal complications.

Iran in transition

Goodarz Danaei, Farshad Farzadfar*, Roya Kelishadi*, Arash Rashidian*, Omid M Rouhani*, Shirin Ahmadnia, Alireza Ahmadvand, Mandana Arabi, Ali Ardalan, Mohammad Arhami, Mohammad Hossein Azizi, Moslem Bahadori, Jill Baumgartner, Arash Beheshtian, Shirin Djalalinia, Leila Doshmangir, Ali Akbar Haghdoost, Rosa Haghshenas, Ahmad Reza Hosseinpoor, Farhad Islami, Farin Kamangar, Davood Khalili, Kaveh Madani, Hossein Masoumi-Asl, Ali Mazyaki, Ali Mirchi, Ehsan Moradi, Touraj Nayernouri, Debbie Niemeier, Amir-Houshang Omidvari, Niloofar Peykari, Farhad Pishgar, Mostafa Qorbani, Kazem Rahimi, Afarin Rahimi-Movaghar, Fahimeh Ramezani Tehrani, Nazila Rezaei, Saeid Shahraz, Amirhossein Takian, Ali Tootee, Majid Ezzati†, Hamid Reza Jamshidi†, Bagher Larijani†, Reza Majdzadeh†, Reza Malekzadeh†*

Being the second-largest country in the Middle East, Iran has a long history of civilisation during which several dynasties have been overthrown and established and health-related structures have been reorganised. Iran has had the replacement of traditional practices with modern medical treatments, emergence of multiple pioneer scientists and physicians with great contributions to the advancement of science, environmental and ecological changes in addition to large-scale natural disasters, epidemics of multiple communicable diseases, and the shift towards non-communicable diseases in recent decades. Given the lessons learnt from political instabilities in the past centuries and the approaches undertaken to overcome health challenges at the time, Iran has emerged as it is today. Iran is now a country with a population exceeding 80 million, mainly inhabiting urban regions, and has an increasing burden of non-communicable diseases, including cardiovascular diseases, hypertension, diabetes, malignancies, mental disorders, substance abuse, and road injuries.

Search strategy and selection criteria

We initially developed a preliminary conceptual framework based on the existing historical and well documented facts about Iranian history of medicine, followed by a systematic review of Persian and English literature to identify sentinel events or breakthroughs for inclusion in this paper. We then searched PubMed, Google Scholar, and Scientific Information Database (an Iranian database), without any time period limitation and using different combinations of the following search terms restricted to Iran: "Health", "Medicine", "Sciences", "Research", and "Education". Subsequently, we expanded our search to include all relevant papers, books, and historical reports, both in English and Persian. We sorted the extracted milestones and breakthroughs to depict a timeline. We also acquired feedback from renowned experts in the field of Iranian history of medicine at different stages and revised on the basis of their comments and guidance.

Key messages

- Iran is experiencing a transitional period; its population is ageing, risk factors contributing to diseases are changing, and infectious diseases and the burden they impose on the health-care system are being replaced by emerging non-communicable diseases, including cardiovascular diseases, malignancies, road injuries, and mental health disorders.
- The profile of risk factors predisposing Iranians to various diseases is changing with increasing trends of urbanisation, exacerbating air pollution in most Iranian megacities, and the increasing prevalence of substance abuse among the youth.
- The increasing burden of non-communicable diseases as well as ecological challenges, including air pollution and water crisis; the inefficient infrastructure of the Iranian health system, especially in preventive care; and weak intersectoral partnership to overcome these issues should be the priorities of any framework to address future health challenges in Iran.



Figure 1: **Tertiary education attainment rate in Iranian female university students**

Figure 2: **Avicenna**



Figure 3: **Timeline of major sociopolitical events in Iranian history from 1785 to 2018**



Figure 4: **Total fertility rate in Iran, the Middle East and North Africa, and globally**



Figure 5: **Timeline of major events in medical education in Iran from 1851 to 2016**



Figure 6: **Timeline of major events in Iran to address public health challenges and infectious diseases from 1850 to 1978**



Figure 7: **Trends in population size (A), life-expectancy at birth (B), under-5 years' mortality (C), and adult mortality (D) in Iran from 1970 to 2015**

	1990 (95% UIs)	2016 (95% UIs)	2030 (95% UIs)
Death rate due to exposure to forces of nature (per 100 000 population)	13·4 (3·2–23·5)	0·1 (0–0·1)	1·9 (0·6–3·2)
Prevalence of stunting in children younger than 5 years (%)	26·1 (21·7–30·3)	7·9 (5·8–10·4)	4·3 (2·9–6·5)
Prevalence of wasting in children younger than 5 years (%)	10·6 (8·9–12·4)	4·8 (3·6–6·4)	4·6 (2·6–7·9)
Prevalence of overweight in children aged 2–4 years (%)	6·5 (2·9–12·3)	19·5 (10·5–32·0)	24·7 (7·6–48·3)
Maternal mortality ratio (maternal deaths per 100 000 livebirths) in women aged 10–54 years	39·9 (26·5–58·4)	13·8 (9·6–19·0)	7·7 (2·8–17·2)
Proportion of births attended by skilled health personnel (%)	88·8 (81·8–93·5)	98·2 (97·0–99·0)	99·1 (97·5–99·8)
Under-5-years' mortality rate (probability of dying before the age of 5 years per 1000 livebirths)	67·4 (57·7–79·0)	17·8 (12·6–24·5)	9·3 (3·4–19·9)
Neonatal mortality rate (probability of dying during the first 28 days of life per 1000 livebirths)	31·0 (26·4–36·)	10·9 (7·7–15·0)	6·3 (2·3–13·5)
Age-standardised rate of new HIV infections (per 1000 population)	0 (0–0)	0 (0–0)	0 (0–0)
Age-standardised rate of tuberculosis cases (per 100 000 population)	25·0 (22·5–27·7)	20·0 (18·0–22·2)	14·3 (12·6–16·1)
Age-standardised rate of malaria cases (per 1000 population)	13·1 (0–102·0)	0 (0–0)	0 (0–0)
Age-standardised rate of hepatitis B virus infection incidence (per 100 000 population)	2000·9 (1589·8–2483·9)	737·0 (577·5–907·9)	428·7 (327·7–540·9)
Age-standardised prevalence of the sum of 15 neglected tropical diseases (%)	3·0 (2·7–3·3)	2·8 (2·4–3·3)	2·8 (2·3–3·2)
Age-standardised death rate due to cardiovascular disease, cancer, diabetes, and chronic respiratory disease in populations aged 30–70 years (per 100 000 population)	436·2 (367·1–514·8)	346·1 (285·8–410·7)	265·3 (157·4–428·2)
Age-standardised death rate due to self-harm (per 100 000 population)	6·5 (5·1–8·1)	6·0 (4·8–7·4)	5·6 (3·1–9·3)
Risk-weighted prevalence of alcohol consumption, as measured by the summary exposure value for alcohol use (%)	0 (0–0)	0 (0–0)	0 (0–0)
Age-standardised death rate due to road injuries (per 100 000 population)	59·9 (50·3–71·4)	34·8 (29·0–42·3)	18·0 (10·0–30·8)
Proportion of women of reproductive age (15–49 years) who have their need for family planning satisfied with modern methods (%)	55·0 (47·1–62·4)	80·1 (74·4–85·0)	86·3 (76·9–92·6)
Number of livebirths per 1000 women aged 10–14 years and women aged 15–19 years	44·1 (37·4–51·2)	14·4 (6·2–28·8)	7·7 (1·2–25·4)
Coverage of essential health services, as defined by the UHC index consisting of the coverage of nine tracer interventions and risk-standardised death rates from 32 causes amenable to personal health care (scale of 0–100)	55·0 (51·9–57·9)	67·5 (64·0–70·7)	72·8 (69·1–76·2)
Age-standardised death rate attributable to household air pollution and ambient air pollution (per 100 000 population)	88·8 (76·7–103·0)	62·6 (51·2–73·8)	48·9 (39·9–58·5)
Age-standardised death rate attributable to unsafe water, sanitation, and hygiene (WaSH); per 100 000 population	17·0 (9·8–25·7)	1·8 (1·0–3·0)	0·9 (0·4–1·6)
Age-standardised death rate due to unintentional poisonings (per 100 000 population)	6·2 (3·6–9·9)	1·5 (1·2–2·4)	0·7 (0·3–1·5)
Age-standardised prevalence of daily smoking in populations aged 10 years or more (%)	12·1 (10·6–14·0)	11·00 (10·0–12·3)	10·7 (8·3–13·6)
Geometric mean of the coverage of eight vaccines, conditional on inclusion in national vaccine schedules, in target populations (%)	90·1 (87·6–92·0)	99·9 (99·8–99·9)	100·0 (99·9–100·0)
Age-standardised prevalence of women aged 15 years or more who experienced physical or sexual violence by an intimate partner in the past 12 months (%)	44·8 (39·9–49·7)	36·9 (32·7–41·2)	34·0 (29·5–38·8)

Als Oxalate, systematisch Ethandioate, werden die Salze und Ester der Oxalsäure bezeichnet. Als Produkt des unvollständigen Kohlenhydrat-Abbaus kommen Oxalate in fast allen Pflanzen vor.
Bekannte Pflanzen mit einem sehr hohen Anteil an Oxalaten sind Weißer Gänsefuß und der Wiesen-Sauerampfer. Auch die Wurzeln und Blätter des Rhabarbers und des Buchweizens enthalten sehr hohe Konzentrationen an Oxalaten.
Andere essbare Pflanzen mit signifikanten Mengen an Oxalat sind die Sternfrucht, Schwarzer Pfeffer, Petersilie, Mohnsamen, Amarant, Spinat, Mangold, Rote Beete, Heidelbeeren und die meisten Nüsse. Auch Kakao enthält beträchtliche Mengen an Oxalaten. Die Blätter des Teestrauches (Camellia sinensis) nehmen beim Oxalatgehalt sogar einen Spitzenplatz ein, wobei allerdings zu berücksichtigen ist, dass ein Tee aus diesen Blättern letztlich nur vergleichsweise geringe Oxalat-Konzentrationen aufweist, zum einen wegen der geringen Menge an Teeblättern, die für die Zubereitung benötigt werden, zum anderen, weil viele Oxalate nur mäßig wasserlöslich sind. Im Körper von höheren Organismen bilden die Oxalatanionen mit zweiwertigen Metallionen wie Calcium (Ca^{2+}) und zweiwertigen Eisen (Fe^{2+}) bei der Ausscheidung über die Nieren kleine Kristalle. Durch weitere Aggregation können sich hieraus größere Nierensteine bilden. Etwa 80 % aller Nierensteine bestehen aus Calciumoxalat. Neben weiteren Nierenkrankheiten können Oxalate auch für Gicht, Rheumatoide Arthritis und Vulvodynie ursächlich sein.
Cadmium katalysiert die Umwandlung von Vitamin C in die Oxalsäure. Dies kann bei Menschen, die hohen Cadmiumbelastungen ausgesetzt sind, z. B. Rauchern, zu Problemen führen.





JAMA Internal Medicine | Original Investigation

Association of Urinary Oxalate Excretion With the Risk of Chronic Kidney Disease Progression

IMPORTANCE Oxalate is a potentially toxic terminal metabolite that is eliminated primarily by the kidneys. Oxalate nephropathy is a well-known complication of rare genetic disorders and enteric hyperoxaluria, but oxalate has not been investigated as a potential contributor to more common forms of chronic kidney disease (CKD).

OBJECTIVE To assess whether urinary oxalate excretion is a risk factor for more rapid progression of CKD toward kidney failure.

DESIGN, SETTING, AND PARTICIPANTS This prospective cohort study assessed 3123 participants with stages 2 to 4 CKD who enrolled in the Chronic Renal Insufficiency Cohort study from June 1, 2003, to September 30, 2008. Data analysis was performed from October 24, 2017, to June 17, 2018.

EXPOSURES Twenty-four–hour urinary oxalate excretion.

MAIN OUTCOMES AND MEASURES A 50% decline in estimated glomerular filtration rate (eGFR) and end-stage renal disease (ESRD).

RESULTS This study included 3123 participants (mean [SD] age, 59.1 [10.6] years; 1414 [45.3%] female; 1423 [45.6%] white). Mean (SD) eGFR at the time of 24-hour urine collection was 42.9 (16.8) mL/min/1.73 m^2. Median urinary excretion of oxalate was 18.6 mg/24 hours (interquartile range [IQR], 12.9-25.7 mg/24 hours) and was correlated inversely with eGFR (r = −0.13, P < .001) and positively with 24-hour proteinuria (r = 0.22, P < .001). During 22 318 person-years of follow-up, 752 individuals reached ESRD, and 940 individuals reached the composite end point of ESRD or 50% decline in eGFR (CKD progression). Higher oxalate excretion was independently associated with greater risks of both CKD progression and ESRD: compared with quintile 1 (oxalate excretion, <11.5 mg/24 hours) those in quintile 5 (oxalate excretion, ≥27.8 mg/24 hours) had a 33% higher risk of CKD progression (hazard ratio [HR], 1.33; 95% CI, 1.04-1.70) and a 45% higher risk of ESRD (HR, 1.45; 95% CI, 1.09-1.93). The association between oxalate excretion and CKD progression and ESRD was nonlinear and exhibited a threshold effect at quintiles 3 to 5 vs quintiles 1 and 2. Higher vs lower oxalate excretion (at the 40th percentile) was associated with a 32% higher risk of CKD progression (HR, 1.32; 95% CI, 1.13-1.53) and 37% higher risk of ESRD (HR, 1.37; 95% CI, 1.15-1.63). Results were similar when treating death as a competing event.

CONCLUSIONS AND RELEVANCE Higher 24-hour urinary oxalate excretion may be a risk factor for CKD progression and ESRD in individuals with CKD stages 2 to 4.

Table 1. Characteristics of Chronic Renal Insufficiency Cohort Study Participants According to Quintiles of 24-Hour Urinary Oxalate[a]

Characteristic	All Participants (n = 3123)	Quintile 1 (n = 625)	Quintile 2 (n = 625)	Quintile 3 (n = 624)	Quintile 4 (n = 626)	Quintile 5 (n = 623)	*P* Value for Group Difference
Urinary oxalate, mg/24 h	18.6 (12.9-25.7)	1.4-11.4	11.5-16.1	16.2-21.0	21.1-27.7	27.8-102.1	NA
Age, y	59.1 (10.6)	59.4 (10.6)	59.1 (10.6)	59.0 (10.7)	59.5 (10.9)	58.6 (9.9)	.54
Female, No. (%)	1414 (45.3)	353 (56.5)	328 (52.5)	304 (48.7)	239 (38.2)	190 (30.5)	<.001
Race, No. (%)							
White	1423 (45.6)	280 (44.8)	284 (45.4)	284 (45.5)	280 (44.7)	295 (47.4)	.03
Black	1278 (40.9)	276 (44.2)	254 (40.6)	237 (38.0)	249 (39.8)	262 (42.1)	
Hispanic	295 (9.5)	44 (7.0)	60 (9.6)	80 (12.8)	63 (10.1)	48 (7.7)	
Other	127 (4.1)	25 (4.0)	27 (4.3)	23 (3.7)	34 (5.4)	18 (2.9)	
Hypertension, No. (%)	2772 (88.9)	529 (84.8)	547 (87.5)	556 (89.1)	575 (92.0)	565 (90.8)	<.001
Diabetes, No. (%)	1507 (48.3)	231 (37.0)	273 (43.7)	314 (50.3)	314 (50.2)	375 (60.2)	<.001
SBP, mm Hg	126.2 (21.2)	125.7 (22.3)	126.3 (21.5)	126.0 (21.6)	125.6 (19.9)	127.6 (20.7)	.48
BMI	32.1 (7.7)	31.1 (7.3)	31.7 (7.5)	31.6 (7.2)	32.4 (8.1)	33.6 (8.3)	<.001
PVD, No. (%)	228 (7.3)	33 (5.3)	41 (6.6)	54 (8.7)	53 (8.5)	47 (7.5)	.12
CHF, No. (%)	307 (9.8)	61 (9.8)	67 (10.7)	63 (10.1)	61 (9.7)	55 (8.8)	.86
Any CVD, No. (%)	1094 (35.0)	225 (36.0)	206 (33.0)	212 (34.0)	225 (35.9)	226 (36.3)	.66
MI or revascularization, No. (%)	714 (22.9)	152 (24.3)	126 (20.2)	133 (21.3)	145 (23.2)	158 (25.4)	.17
Previous stroke, No. (%)	326 (10.4)	70 (11.2)	69 (11.0)	54 (8.7)	67 (10.7)	66 (10.6)	.59
Current smoking, No. (%)	371 (11.9)	89 (14.2)	72 (11.5)	78 (12.5)	70 (11.2)	62 (10.0)	.19
Medication use, No. (%)							
ACEI/ARB	2184 (70.1)	380 (60.9)	421 (67.4)	440 (70.9)	470 (75.3)	473 (76.3)	<.001
β-Blocker	1569 (50.4)	305 (48.9)	324 (51.8)	318 (51.2)	315 (50.5)	307 (49.5)	.83
Statin	1856 (59.6)	332 (53.2)	349 (55.8)	375 (60.4)	404 (64.7)	396 (63.9)	<.001
Antiplatelet	1572 (50.5)	288 (46.2)	314 (50.2)	313 (50.4)	331 (53.0)	326 (52.6)	.12
Loop diuretic	1190 (38.2)	228 (36.5)	245 (39.2)	248 (39.9)	226 (36.2)	243 (39.2)	.54
Thiazide diuretic	870 (27.9)	121 (19.4)	161 (25.8)	180 (29.0)	191 (30.6)	217 (35.0)	<.001
Phosphate binder	228 (7.3)	46 (7.4)	50 (8.0)	43 (6.9)	50 (8.0)	39 (6.3)	.74
SCr, mg/dL	1.8 (0.8)	1.7 (0.7)	1.8 (0.8)	1.9 (0.9)	1.9 (0.7)	2.0 (0.8)	<.001
eGFR, mL/min/1.73 m^2	42.9 (16.8)	46.9 (17.8)	44.5 (17.8)	41.6 (17.0)	40.8 (14.9)	40.6 (15.4)	<.001
≥45	1311 (42.0)	329 (52.6)	280 (44.8)	242 (38.8)	234 (37.4)	226 (36.3)	<.001
30-44	1046 (33.5)	175 (28.0)	205 (32.8)	208 (33.3)	221 (35.3)	237 (38.0)	
<30	766 (24.5)	121 (19.4)	140 (22.4)	174 (27.9)	171 (27.3)	160 (25.7)	
Urine ACR, mg/g	39.7 (7.5-362.6)	19.4 (6.0-130.7)	23.0 (6.4-281.3)	52.8 (8.7-504.0)	45.2 (8.9-350.3)	102.7 (11.8-560.7)	<.001
Urinary protein, mg/24 h	154 (67-810)	100 (53-338)	121 (64-594)	184 (68-915)	180 (77-876)	379 (94-1678)	<.001
Serum albumin, g/dL	4.1 (0.4)	4.1 (0.4)	4.1 (0.4)	4.0 (0.5)	4.1 (0.4)	4.0 (0.5)	.05
Hemoglobin, g/dL	12.8 (1.8)	12.9 (1.7)	12.9 (1.8)	12.7 (1.7)	12.9 (1.8)	12.8 (1.8)	.20
Phosphate, mg/dL	3.8 (1.0)	3.8 (1.0)	3.8 (0.8)	4.0 (1.2)	3.9 (1.0)	3.8 (1.0)	.02

Table 2. Factors Associated With 24-Hour Urinary Oxalate Excretion[a]

	Univariable		Multivariable Adjusted	
Factor	β Coefficient	*P* Value	β Coefficient	*P* Value
Age (per 10 y)	−0.01	.18	0.01	.13
Female vs male	−0.20	<.001	0.04	.10
Black vs nonblack	−0.03	.18	−0.12	<.001
Diabetes	0.17	<.001	0.11	<.001
BMI (per 5 units)	0.04	<.001	0.01	.33
Current smoking	−0.09	.002	−0.05	.05
ACEI or ARB use	0.14	<.001	0.01	.62
β-Blocker	0.01	.76	−0.03	.15
Loop diuretic	0.02	.36	−0.05	.02
Thiazide diuretic	0.14	<.001	0.11	<.001
Phosphate binder	−0.02	.65	0.03	.41
eGFR (per 10 mL/min/1.73 m^2)	−0.04	<.001	−0.03	<.001
Natural log urinary protein (per mg/24 h)	0.08	<.001	0.03	<.001
Serum albumin (per g/dL)	−0.07	.002	0.08	.001
Hemoglobin (per g/dL)	−0.01	.09	0.00	.54
Phosphate (per mg/dL)	0.01	.26	−0.01	.43
Calcium (per mg/dL)	−0.16	<.001	−0.11	<.001
Urinary calcium (per 10 mg/24 h)	−0.02	<.001	−0.02	<.001
Urinary creatinine (per 100 mg/24 h)	0.03	<.001	0.04	<.001

Table 3. Risk of CKD Progression and ESRD According to Ascending Quintiles of 24-Hour Urinary Oxalate Excretion

Variable	Quintile 1	Quintile 2	Quintile 3	Quintile 4	Quintile 5	*P* Value for Difference
Oxalate excretion, mg/24 h	1.4-11.4	11.5-16.1	16.2-21.0	21.1-27.7	27.8-102.1	NA
No. of participants	625	625	624	626	623	NA
CKD Progression						
No. of events	133	156	223	199	229	NA
Event rate per 1000 patient-years	3.80	4.56	6.89	6.21	7.16	NA
Hazard ratio (95% CI)						
Multivariable model 1[a]	1 [Reference]	1.21 (0.96-1.54)	1.86 (1.49-2.32)	1.89 (1.50-2.38)	2.32 (1.83-2.93)	<.001
Multivariable model 2[b]	1 [Reference]	1.06 (0.84-1.35)	1.66 (1.32-2.08)	1.55 (1.23-1.96)	1.83 (1.44-2.33)	<.001
Multivariable model 3[c]	1 [Reference]	0.94 (0.74-1.20)	1.35 (1.07-1.69)	1.14 (0.90-1.45)	1.33 (1.04-1.70)	.003
ESRD						
No. of events	99	128	171	168	186	NA
Event rate per 1000 patient-years	2.38	3.18	4.44	4.37	4.90	NA
Hazard ratio (95% CI)						
Multivariable model 1[a]	1 [Reference]	1.46 (1.11-1.91)	2.01 (1.56-2.60)	2.29 (1.75-2.98)	2.78 (2.12-3.65)	<.001
Multivariable model 2[b]	1 [Reference]	1.29 (0.98-1.69)	1.85 (1.42-2.40)	1.93 (1.48-2.52)	2.19 (1.66-2.88)	<.001
Multivariable model 3[c]	1 [Reference]	1.05 (0.79-1.39)	1.45 (1.11-1.89)	1.36 (1.04-1.78)	1.45 (1.09-1.93)	.008

Abbreviations: CKD, chronic kidney disease; ESRD, end-stage renal disease; NA, not applicable.

[a] Stratified by site and adjusted for age, sex, race/ethnicity, systolic blood pressure, diabetes, body mass index, and 24-hour urinary creatinine excretion.

[b] Adjusted for model 1 plus medications (phosphate binders, angiotensin II receptor blockers, angiotensin-converting enzyme inhibitors, diuretics, β-blockers, statins, antiplatelet agents), hemoglobin, and serum albumin.

[c] Adjusted for model 1 and model 2 plus baseline estimated glomerular filtration rate.

Figure 1. Urinary Oxalate Excretion and the Risk of 50% Decline in Estimated Glomerular Filtration Rate (eGFR) or End-Stage Renal Disease According to Subgroups

Characteristic	HR (95% CI)
All participants	1.32 (1.13-1.53)
Age, y	
≥61	1.63 (1.28-2.07)
<61	1.12 (0.92-1.38)
Sex	
Male	1.40 (1.13-1.73)
Female	1.24 (0.99-1.56)
Diabetes	
Yes	1.44 (1.17-1.76)
No	1.13 (0.88-1.44)
BMI	
≥32.1	1.45 (1.15-1.82)
<32.1	1.26 (1.02-1.55)
Race	
Black	1.21 (0.99-1.49)
Nonblack	1.48 (1.17-1.87)
Proteinuria	
≥154 mg/24 h	1.16 (0.97-1.37)
<154 mg/24 h	1.37 (0.95-1.98)
eGFR	
≥30 mL/min/1.73 m^2	1.30 (1.05-1.62)
<30 mL/min/1.73 m^2	1.41 (1.12-1.76)
Medications	
ACEI/ARB	1.32 (1.11-1.58)
No ACEI/ARB	1.30 (0.93-1.81)
Statin	1.35 (1.11-1.64)
No statin	1.21 (0.94-1.56)
Diuretic	1.43 (1.19-1.71)
No diuretic	1.08 (0.82-1.44)
Other laboratory values	
Albumin ≥4.1 g/dL	1.32 (1.02-1.70)
Albumin <4.1 g/dL	1.27 (1.05-1.54)
Phosphorus ≥3.8 mg/dL	1.56 (1.27-1.93)
Phosphorus <3.8 mg/dL	1.08 (0.86-1.35)
Calcium ≥9.3 mg/dL	1.23 (0.98-1.55)
Calcium <9.3 mg/dL	1.30 (1.06-1.60)
Urine calcium ≥41 mg/24 h	1.44 (1.10-1.89)
Urine calcium <41 mg/24 h	1.26 (1.04-1.53)



Figure 2. Urinary Oxalate Excretion and the Risk of End-Stage Renal Disease According to Subgroups

Characteristic	HR (95% CI)
All participants	1.37 (1.15-1.63)
Age, y	
≥61	1.63 (1.24-2.15)
<61	1.17 (0.93-1.48)
Sex	
Male	1.40 (1.10-1.78)
Female	1.22 (0.94-1.59)
Diabetes	
Yes	1.53 (1.22-1.93)
No	1.07 (0.80-1.41)
BMI	
≥32.1	1.72 (1.31-2.24)
<32.1	1.15 (0.91-1.46)
Race	
Black	1.16 (0.92-1.46)
Nonblack	1.61 (1.23-2.10)
Proteinuria	
≥154 mg/24 h	1.30 (1.08-1.58)
<154 mg/24 h	1.05 (0.64-1.70)
eGFR	
≥30 mL/min/1.73 m^2	1.19 (0.90-1.58)
<30 mL/min/1.73 m^2	1.55 (1.23-1.95)
Medications	
ACEI/ARB	1.35 (1.10-1.65)
No ACEI/ARB	1.45 (1.00-2.09)
Statin	1.31 (1.05-1.64)
No statin	1.41 (1.05-1.89)
Diuretic	1.49 (1.21-1.83)
No diuretic	1.02 (0.73-1.42)
Other laboratory values	
Albumin ≥4.1 g/dL	1.18 (0.87-1.60)
Albumin <4.1 g/dL	1.41 (1.14-1.75)
Phosphorus ≥3.8 mg/dL	1.62 (1.29-2.04)
Phosphorus <3.8 mg/dL	1.08 (0.82-1.42)
Calcium ≥9.3 mg/dL	1.05 (0.80-1.38)
Calcium <9.3 mg/dL	1.60 (1.26-2.02)
Urine calcium ≥41 mg/24 h	1.32 (0.96-1.83)
Urine calcium <41 mg/24 h	1.40 (1.13-1.73)



Key Points

Question Does higher urinary oxalate excretion predispose patients to kidney failure?

Findings In this cohort study of 3123 individuals with chronic kidney disease, higher urinary excretion of oxalate was associated with a 37% greater adjusted risk of future end-stage kidney disease.

Meaning Urinary oxalate excretion appears to be an independent risk factor for chronic kidney disease progression.

Laboratory Measurements

Urinary oxalate was measured at the Mayo Clinic (Rochester, Minnesota) using an oxalate oxidase enzymatic assay. Frozen samples were received, thawed, and then measured for pH. Samples with pH 8 or higher were rejected and not processed (76 of >3000) because of concern for bacterial contamination. Before oxalate measurement, sample pH was adjusted to 2.5 to 3.0 with phosphate buffer (pH 2.5), and nitrite was added to remove interference from ascorbic acid. The interassay coefficients of variation, measured from 249 masked split replicate samples collected from an individual with CKD whose urine samples were aliquoted into tubes identical to CRIC study tubes, were less than 3%. The 24-hour urinary oxalate excretion was calculated by multiplying the oxalate concentration by the urinary volume and then adjusting for the number of hours collected.

A 58-year-old man was hospitalised in the intensive care unit for severe acute respiratory distress syndrome caused by an influenza infection. After 31 days, he was gradually weaned off mechanical ventilation. However, on the day after extubation, he had to be reintubated because of further respiratory distress. The procedure was complicated by cardiac arrest. Looking at the ECG, can you say why the cardiac arrest might have happened?



- Acute coronary syndrome
- Succinylcholine induced hyperkalaemia
- Anaphylactic reaction
- Malignant hyperthermia

Suxamethonium oder Succinylcholin (auch bekannt als Succinylbischolin oder Succinyldicholin) ist das einzige in der Humanmedizin verwendete depolarisierende Muskelrelaxans. Es wird angewendet, um eine vorübergehende Muskellähmung (auch der Atemmuskulatur) herbeizuführen und dadurch eine Beatmung zu ermöglichen. Die Substanz wirkt als Agonist an den Acetylcholinrezeptoren der motorischen Endplatte. Durch eine Dauerdepolarisation (Übererregung) kommt es schließlich zur Muskellähmung (Depolarisationsblock).
Der maximale Wirkungseintritt von Succinylcholin ist schnell (etwa 1 Minute) und die Wirkungsdauer kurz (3–10 Minuten). Die intravenös, in einer Dosierung von 1–1,5 mg/kg Körpergewicht, zu verabreichende Substanz gilt in der klinischen Anästhesie als Muskelrelaxans der Wahl zur Narkoseeinleitung bei nicht-nüchternen Patienten (Rapid Sequence Induction), die ein erhöhtes Risiko für eine Aspiration haben. Eliminiert wird die Substanz in Leber und im Plasma über die Pseudocholinesterase. Durch den Wirkmechanismus der Substanz werden vor Einsetzen der Lähmung kurzzeitig Muskelzuckungen (Faszikulationen) individuell unterschiedlicher Stärke ausgelöst. Ein durch die Faszikulationen ausgelöster Untergang von Muskelzellen kann zum kritischen Anstieg des Serum-Kalium-Wertes und entsprechenden Komplikationen (Herzrhythmusstörungen, Bradykardien, Herz-Kreislauf-Stillstand) führen.



Bei Patienten mit Erkrankungen, bei denen eine Störung der Stabilität der Zellmembranen besteht (etwa Verbrennungskrankheit, Polytrauma) sollte die Substanz daher nicht verwendet werden. Bei Patienten, die über eine längere Zeit immobil waren (beispielsweise durch Bettlägerigkeit) kann es durch eine erhöhte Empfindlichkeit der Acetylcholinrezeptoren ebenfalls zu den genannten Komplikationen kommen.